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Wei Zhao 
DECREASED JMJD3 EXPRESSION IN MESENCHYMAL STEM CELLS CONTRIBUTES TO LONG-
TERM SUPPRESSION OF OSTEOBLAST DIFFERENTIATION IN MULTIPLE MYELOMA 
 
Multiple myeloma (MM) is the most frequent cancer to involve the skeleton, 
with over 80% of myeloma patients developing lytic bone disease (MMBD). Importantly, 
MM-associated bone lesions rarely heal even when patients are in complete remission. 
Bone marrow stromal cells (BMSCs) isolated from MM patients have a distinct genetic 
profile and an impaired osteoblast (OB) differentiation capacity when compared to 
BMSCs from healthy donors. Utilizing an in vivo model of MMBD and patient samples, 
we showed that BMSCs from tumor-bearing bones failed to differentiate into OBs weeks 
after removal of MM cells. Both Runx2 and Osterix, the master transcription factors for 
OB differentiation, remained suppressed in these BMSCs.  However, the molecular 
mechanisms for MM-induced long-term OB suppression are poorly understood.  
We characterized both Runx2 and Osterix promoters in murine pre-osteoblast 
MC4 cells by chromatin immunoprecipitation (ChIP). The transcriptional start sites (TSSs) 
of Runx2 and Osterix in untreated MC4 cells were co-occupied by transcriptionally active 
histone 3 lysine 4 tri-methylation (H3K4me3) and transcriptionally repressive histone 3 
lysine 27 tri-methylation (H3K27me3), termed the “bivalent domain”. These bivalent 
domains became transcriptionally silent with increasing H3K27me3 levels when MC4 
cells were co-cultured with MM cells or treated with TNF-α, an inflammatory cytokine 
increased in MM bone marrow microenvironment. The increasing H3K27me3 levels 
vi 
induced by MM cells or TNF-α were associated with the downregulation of the H3K27 
demethylase JMJD3 in MC4 cells and murine BMSCs.  Knockdown of JMJD3 in MC4 cells 
was sufficient to inhibit OB differentiation. Further, ectopic overexpression of JMJD3 in 
MC4 cells partially rescued the suppression of osteoblast differentiation induced by TNF-
a. We also found that pre-incubation of MC4 cells with the NF-kB inhibitor quinazoline 
(QNZ) before TNF-a treatment prevented the downregulation of JMJD3. In agreement 
with our in vitro findings, BMSCs from MM patients had persistently decreased JMJD3 
expression compared to healthy BMSCs. 
Our findings together demonstrate that decreased JMJD3 expression in BMSCs 
contributes to the long-term OB suppression in MMBD by remodeling histone 
landscapes at the Runx2 and Osterix TSSs. Thus, developing strategies to restore JMJD3 
expression in BMSCs should increase bone formation and possibly decrease tumor 
burden in MM. 
 
G. David Roodman, M.D., Ph.D., Chair 
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CHAPTER 1 
 INTRODUCTION 
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1.1 Current Understanding of MMBD 
 
MM is the most common cancer that involves skeleton. 70% of newly diagnosed 
MM patients are found to have bone lesions, which eventually affect an additional 20% 
of patients as the disease progresses1. Symptomatic patients frequently complain of 
debilitating bone pain in the back or chest, although pain in extremities is also seen. 
Bone pain can be triggered by any movement and is characteristically absent during 
sleep. Pathologic fractures can occur in up to 60% of MM patients with no apparent 
trauma history and cause loss of vertebral height if vertebrae are involved or 
neurovascular damage if long bones are involved2. Also, as the largest calcium reservoir 
in the body, bone destruction can increase blood calcium levels beyond physiological 
range. MM patients with hypercalcemia suffer from anorexia, nausea, vomiting, 
confusion, fatigue, constipation, renal stones, depression and/or polyuria. Thus, MMBD 
severely impairs the patients’ quality of life and more importantly increases the 
mortality rate by 20%3.  
Bone is maintained by constantly undergoing formation and resorption, a 
lifelong process called bone remodeling4-6. In adults, 10% of skeleton is replaced each 
year. Bone remodeling is necessary to repair accumulating micro-damage and to 
transform the woven bone into lamellar structures during the fracture healing process. 
At the microscopic level, bone remodeling is mediated by the coupled function of two 
types of bone cells: the osteoblast that produces bone and the osteoclast that resorbs 
bone. Bone formation by osteoblasts and resorption by osteoclasts are delicately 
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balanced by cytokines and cell-to-cell interactions so that no more or less bone is 
formed7. One of the mechanisms by which osteoblasts and osteoclasts communicate 
with each other is the bidirectional signaling between the surface receptor EphB4 on 
osteoblasts and its membrane-bound ligand Ephrin B2 on osteoclasts. The forward 
signaling following EphB4 activation promotes osteoblast differentiation, and the 
reverse signaling following Ephrin B2 activation simultaneously suppresses osteoclast 
differentiation8,9. Another established mechanism involves expression of receptor 
activator of NF-kB ligand (RANKL) and its soluble decoy receptor osteoprotegerin (OPG) 
by BMSCs and osteoblasts. Upon binding to receptor activator NF-kB (RANK) on 
osteoclast precursors, RANKL potently stimulates osteoclast differentiation, activation 
and survival by activating NF-kB, MAPKs and calcineurin/nuclear factor of activated T 
cells (NFATc1), the master transcription factor of osteoclastogenesis10,11. Neutralizing 
RANKL with the monoclonal antibody Denosumab effectively blocks 
osteoclastogenesis12. Similar to Denosumab, OPG, an endogenous RANKL decoy 
receptor, also plays a major role in negatively regulating osteoclasts13. These results 
demonstrate that BMSCs and osteoblasts either promote or inhibit osteoclast 
differentiation depending on the RANKL/OPG ratio, which varies in response to a variety 
of hormones, such as vitamin D314, PTH15, and prostaglandins16. The balanced coupling 
between osteoblasts and osteoclasts, however, can be severely disturbed in 
inflammatory and neoplastic bone diseases. 
 MM has unique features compared to other cancers frequently metastasizing to 
bones, such as breast and prostate cancer. Like those cancers, myeloma activates 
4 
osteoclasts by directly secreting osteoclastogenic activating factors (OAFs) and inducing 
other cells in bone marrow microenvironment to secrete OAFs (Figure 1). Cytokines 
identified as OAFs in MM include RANKL, TNF-a, MIP-1a, IL1, IL-617, Activin A18 and 
Annexin II19. RANKL as discussed already is a critical factor for osteoclast differentiation, 
activation and survival. TNF-a synergizes with RANKL to accelerate osteoclast 
differentiation mainly by increasing the expression of downstream mediators c-Src, 
TRAF2, TRAF6, and MEKK120. Also, TNF-a increases RANKL expression in BMSCs and 
osteoblasts. Although elevated quantities of TNF-a have been reported in serum and 
bone marrow of MM patients, it’s still unclear whether myeloma cells themselves make 
a major contribution to the elevated TNF-a levels21. MIP-1a, produced by myeloma cells, 
belongs to the CC chemokine family and plays an important role in attracting osteoclast 
precursors and differentiating them into mature osteoclasts independent of RANKL22-25. 
Serum levels of MIP-1a correlate with the severity of bone lesions and survival of MM 
patients26. IL-1b is another important factor that regulates different stages of osteoclast 
differentiation.  Since osteoclast precursors don’t initially express its receptor IL-1R1, 
the promoting effects of IL-1b depends on RANK/RANKL signaling which creates a 
permissive environment by upregulating IL-1R1 on osteoclast precursors27. Importantly, 
the overactive osteoclasts destroy bones, releasing growth factors buried in the bone 
osteoid matrix to support myeloma growth. The reciprocity between MM cell-induced 
osteoclast formation and osteoclasts releasing growth factors from bone to increase 
MM cell growth is known as “vicious cycle” and underlines the importance of controlling 
MMBD to reduce tumor burden.  
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Unlike other cancers, myeloma markedly suppresses osteoblast differentiation 
and functionality by producing or inducing osteoblast inhibitory factors, including DKK1, 
sclerostin, TNF-a, IL-1b and IL-7, or by direct cell adhesion with BMSCs which activates 
NF-kB and p38 signaling in BMSCs (Figure 1). Wnts are soluble glycoproteins in bone 
marrow microenvironment that play a pivotal role in osteoblastogenesis by engaging 
their membrane-bound receptor complexes Frizzled/LRP5/628-30. Of three well 
characterized pathways activated by Wnts, the canonical pathway involving b-catanin 
stabilization and transcriptional activation is responsible for most of its effects on 
osteoblasts31. Derangement of Wnt signaling has been reported to result in skeletal 
abnormality. For example, a loss of function mutation of LRP5 causes osteoporosis-
pseudoglioma syndrome. Patients with this syndrome suffer from vision problems and 
osteoporotic fractures with an early onset32. DKK1 and sclerostin are natural antagonists 
of Wnt signaling that sequester LRP5/6. Elevated production of DKK1 in myeloma cells, 
as shown by immunohistochemistry (IHC) of bone marrow in MM patients, correlates 
with the presence of bone lesions33. In further support of DKK1’s involvement in MMBD, 
treating SCID mice engrafted with primary MM cells with DKK1 neutralizing antibodies 
prevents progressive bone loss34. Similar to DKK1, Sclerostin which is predominantly 
produced by mature osteocytes also contributes to the pathogenesis of MMBD35-37. 
Secretion of Sclerostin from osteocytes is greatly enhanced by contact with myeloma 
cells38. Blockade of sclerostin by either genetic deletion or neutralizing antibodies in 
mouse models of MMBD inhibits the development of lytic lesions and increases 
circulating levels of osteoblast activity markers39. TNF-a is another well recognized 
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inhibitor of osteoblast differentiation through mechanisms independent of disrupting 
Wnt signaling. Upon binding to its receptor TNFR1, TNF-a triggers trimerization of the 
receptor, subsequently recruits tumor necrosis factor receptor type 1-associated death 
domain protein (TRADD) as the initiating event, and eventually culminates in the 
activation of NF-kB, JNK, p38, ERK, and caspases.  Nevertheless, the molecular map of 
TNF-a signaling hasn’t been conclusively defined40. It has been reported that inhibition 
of NF-kB or JNK activation in osteoblast precursors partially restores the suppression of 
osteoblast differentiation by TNF-a41,42. Regardless of the individual signaling pathways 
involved, TNF-a rapidly downregulates the expression of both Runx2 and Osterix in 
osteoblast precursors, which are the master transcription factors indispensable for 
normal osteoblastogenesis.  Of note, MM patients have higher serum levels of TNF-a 
compared to normal donors.  
Current pharmacologic treatments for MMBD target the elevated activity of 
osteoclasts in patients. Bisphosphonate therapy is the mainstay for treating MMBD43-45. 
Their anti-catabolic effects result from enhanced osteoclast apoptosis partly due to the 
inhibition of the mevalonate pathway46. Bisphosphonate therapy may also have direct 
cytotoxic effects on tumor cells and alter tumor-stromal cell interactions47. However, 
bisphosphonate therapy only decreases skeletal-related events by 50% and is associated 
with a low incidence of serious adverse effects, including renal impairment and 
osteonecrosis of the jaw (ONJ)48. Another drug option currently under investigation in 
MM is denosumab49, which binds receptor activator of nuclear factor kappa-B ligand 
(RANKL) with high affinity and disrupts RANKL-RANK interaction on osteoclasts, 
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preventing their maturation. Denosumab is also associated with ONJ and can also result 
in increased infections because of RANKL’s role in the immune system50,51. In addition to 
unfavorable side effects of anti-catabolic therapy, effective anabolic agents targeting 
suppressed osteoblasts are generally lacking. Growing knowledge of the molecular 
mechanisms responsible for MMBD should provide more treatment options hopefully in 
the near future. As a result, targeting MMBD using a combination of anabolic and 
anticatabolic medication should also improve MM patient 5-year survival rates. 
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Figure 1: Mechanisms of MMBD 
 
Myeloma cells disrupt the delicate equilibrium of osteoblast activity and osteoclast 
activity by direct cell-cell interaction and inducing a variety of cytokines. The OAFs, 
including RANKL, TNF-a, MIP-1a, IL-1, IL-6, Activin A, Anexin II and others, stimulate 
osteoclast activity, whereas the osteoblast inhibitory factors, including DKK1, Sclerostin, 
TNF-a, IL-1, IL-7 and others, suppress osteoblast activity. Thus, bone resorption by 
osteoclasts is favored over bone formation by osteoblasts, resulting in lytic bone lesions 
in MM patients. 
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1.2 The Role of Gfi1 in Mediating Persistent Suppression of Osteoblast Differentiation in 
MM 
 
Bone lesions in MM patients persist even when patients are in complete 
remission. Several independent studies have shown that BMSCs isolated from MM 
patients (MM-BMSCs) are selectively refractory to potent osteogenic stimuli in vitro in 
the absence of MM cells compared to BMSCs from normal donors (ND-BMSCs), while 
their capacities to differentiate into adipocytes and chondrocytes are not affected52-55. 
Those studies used the plastic adhesion technique to enrich BMSCs, which have to be 
continuously cultured for more than a month until other cell populations die out.  
Considering the time required to obtain homogenous BMSCs, the defects present in 
MM-BMSCs that block their differentiation into osteoblasts are not transient in nature. 
Further, MM-BMSCs have been reported to show other distinct phenotypes from their 
healthy counterparts56-60.   Myeloma cells induce MM-BMSCs to secrete increased levels 
of IL-1b, IL-3, IL-6, IL-10, BAFF, GDF15, TNF-a, TGFb1, DKK1, RANKL and AREG. These 
cytokines create a permissive niche for myeloma growth as well as increase bone 
destruction.  In addition, MM-BMSCs had lower expression of Runx2, Osterix and TAZ 
than ND-BMSCs61,62.   Loss of these master transcription factors of osteoblast 
differentiation may explain the defective osteoblastogenesis in MM-BMSCs. However, it 
is unclear how MM-BMSCs maintain their persistent inability to differentiate into 
osteoblasts. Garayoa and colleagues found several non-recurrent chromosomal gains 
and losses (>1 Mb size) in MM-BMSCs, which hardly explain the anomaly shared by MM-
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BMSCs63.  This knowledge gap encouraged us to investigate the underlying molecular 
mechanism(s) mediating long-term suppression of osteoblast differentiation in MM. 
In 2011, Dr. D’Souza from our group identified the transcription factor, growth 
factor independence 1 (Gfi1), as a potential target involved in the protracted inability of 
MM-BMSCs to differentiate into functional osteoblasts64. The human Gfi1 gene encodes 
a 422 amino-acid protein composed of N-terminal SNAG domain, an intermediate 
domain and C-terminal zinc finger domain. While both the SNAG domain and 
intermediate domain are responsible for protein-protein interaction, the zinc finger 
domain binds to the consensus DNA sequence TAAATCAC(A/T)GCA65,66. Being a 
transcriptional repressor, Gfi1 recruits euchromatin histone-lysine N-methyltransferase 
2 (EHMT2) to specific genomic region, which mono- and dimethylates H3K967. The newly 
created H3K9me marks lead to transformation of transcriptionally active euchromatin to 
transcriptionally silent heterochromatin by interacting with heterochromatin protein 1 
(HP1)68. In addition to its role in H3K9 modification, EHMT2 weakly methylates 
unmodified H3K27 into H3K27me69. This triggers the initial events that progressively 
lead to epigenetic silencing with subsequent participation of the Polycomb Repressive 
Complex 2 (PRC2).  Other identified Gfi1 binding partners include histone deacetylases 
(HDACs) that reduce the accessibility of the transcriptional machinery67, the adaptor 
protein Ajuba that assembles Gfi1 into protein complexes67,70 and p53 that dictates cell 
survival. In line with its interaction with multiple biologically important proteins, Gfi1 
plays a crucial role in regulating hematopoietic stem cell (HSC) quiescence71,72, and B 
and T lymphocyte differentiation73-75.  Mutations in Gfi1 cause autosomal dominant 
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severe congenital neutropenia (SCN), which subjects affected patients to recurrent 
infection76,77. However, no group had ever attempted to investigate the biological 
function of Gfi1 in BMSCs and osteoblasts until Dr. D’ Souza.  
Dr. D’Souza first used an in vivo model of MMBD where mice were injected 
intratibially with saline as control or the murine myeloma cell line 5TGM1 cells that 
stably expressed thymidine kinase (TK) for negative selection and green fluorescence 
protein (GFP) for positive selection. Progressive bone destruction occurs in this model 
over the course of 4 weeks. Compared to BMSCs isolated from saline-injected tibiae, 
BMSCs from MM-bearing tibiae showed persistent defects in osteoblast differentiation 
in absence of myeloma cells for more than one month, as proven by lack of induction of 
osteoblast marker genes and impaired Alizarin Red staining that reflects osteoblast 
mineralization activity by osteoblast differentiating factors. BMSCs isolated from bone 
marrow of mouse models and MM patients had decreased osteoblast differentiation 
with increased expression of Gfi1. To further delineate the molecular mechanisms, a 
plasmid encoding wild-type mouse Gfi1 was co-transfected with the luciferase reporter 
plasmid regulated by mouse Runx2 promoter (-992/+111) into osteoblast precursor 
MC4 cells. The relative luciferase unit (RLU) was inhibited dose-dependently by 
overexpression of wild-type Gfi1, which was also observed by overexpression of 
mutated Gfi1 (N382S) that was thought to abolish DNA binding, suggesting a novel 
binding site of Gfi1 on the Runx2 promoter. Importantly, knockdown of Gfi1 in BMSCs 
from MM patients restored their osteoblast differentiation capacity, implicating Gfi1 in 
establishing and maintaining the defective osteoblastogenesis in MM. 
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Building upon Dr. D’Souza’s work, our collaborator Dr. Adamik found significantly 
decreased levels of transcriptionally active histone marks H3K9ac and H3K4me3, 
increased levels of transcriptionally repressive histone mark H3K27me3, and 
unproductive RNA polymerase II (Pol II) elongation on the Runx2 promoter in MC4 cells 
exposed to myeloma cells78. He localized the -37/-7 region on the Runx2 promoter as 
the predominant binding site of Gfi1. Binding of Gfi1 to this region was sufficient to 
recruit HDAC1 and EZH2, the H3K27 methyltransferase in PRC2. Consistently, stable 
knockdown of Gfi1 in MC4 cells effectively prevented the aggregation of those histone 
modifiers at -37/-7 region and, more importantly, helped MC4 cells escape the 
prolonged epigenetic silencing of Runx2 expression induced by myeloma cells.  Similarly, 
antagonizing Gfi1 using specific inhibitors against HDAC1 (MC1294) and EZH2 (GSK126) 
restored Runx2 gene expression in MC4 cells as well as BMSCs from MM patients, 
thereby reversing MM-mediated suppression of osteoblast differentiation.  Further 
supporting Gfi1’s role in the pathogenesis of MMBD, Dr. Silbermann in our group, using 
a novel inhibitor XRK3F2 that targeted the ZZ domain of sequestosome 1/p62 which 
serves as a platform for formation of signaling complexes, found that p62-ZZ domain 
mediated Gfi1 induction in BMSCs exposed to myeloma cells79.  MicroCT analysis 
showed that XRK3F2 treatment induced dramatic cortical bone formation in MM-
bearing tibiae in mouse models of MMBD described above in this chapter. These results 
collectively demonstrate that epigenetic alteration rather than genetic mutation in MM-
BMSCs could mediate the protracted suppression of osteoblast differentiation in MM. 
They further suggested that targeting histone modifiers could provide new therapeutic 
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options to treat MMBD, although there could be a potential “off-target” effects with 
these treatments. 
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1.3 “Bivalent Domains” and Epigenetic Memory 
 
Runx2 and Osterix are the master transcription factors that regulate osteoblast 
differentiation.  Knockout of either Runx280 or Osterix81 in mice leads to a complete loss 
of both endochondral and intramembranous ossification. They, however, are not the 
only regulators. It’s been suggested that osteoblast differentiation also requires 
concomitant epigenetic remodeling of chromatin landscapes. Histones are repeating 
protein units that organize eukaryotic DNA. Their N-terminal tails are subject to distinct 
modifications, including methylation, acetylation, phosphorylation, ubiquitination and 
sumoylation, which actively control gene transcription by either directly changing the 
interaction of DNA with nucleosomes or recruiting “reader” proteins to modulate the 
accessibility of transcription factors to genomes82. Histone acetylation catalyzed by 
histone acetyltransferases (HATs), for example, neutralizes the positive charge of lysine 
residues, thereby relaxing the interaction between histones and negatively charged 
DNA83. This epigenetic change provides an easier access of transcription machinery to 
the promoter region of associated genes and greatly enhances transcription without 
altering genetic information. Conversely, histone deacetylation catalyzed by histone 
deacetylases (HDACs) shuts down gene transcription84. Unlike histone acetylation, other 
histone modifications that don’t cause net change in charge also affect gene expression 
by recruiting or repelling “reader proteins” in a histone- and sequence-specific manner. 
The chromodomain of heterochromatin protein 1 (HP1) recognizes trimethyl-histone 3 
lysine 9 (H3K9me3) marks via aromatic cage pockets and compacts transcriptionally 
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active euchromatin into transcriptionally silent heterochromatin85. Other protein 
domains that bind histone modifications include Tudor, PWWP, PHD fingers, BAH, and 
ADD86. Interestingly, different combination of adjacent or distant histone modifications 
preferentially recruits certain reader proteins that require complex interaction with 
histone tails. Therefore, studying multiple histone modifications instead of focusing on 
one should provide more insights into the epigenetic landscape.  
The long-lasting regulation of histone modifications on gene expression relies on 
their inheritability across generations, although a certain degree of plasticity is allowed. 
Current models suggest that each daughter cell randomly inherits parental histones, 
which subsequently act as a template to spread the same post-transcriptional 
modification pattern to neighboring native histones82,87. Recycling, splitting and 
redistributing parental histones are facilitated by histone chaperones accumulated at 
the replication fork88-92. This model works flawlessly on long stretches of nucleosomes 
carrying the same marks. However, the epigenetic information may be accidentally lost 
if certain histone modifications exist only in a few nucleosomes. The specific histone 
modification marks that fit into this model have to meet two conditions. First, this 
histone modification is relatively stable to merit its role in “epigenetic memory”. The 
histone modifications that are easily erased in daughter cells don’t present a consistent 
inheritance pattern. A number of studies have shown that histone methylation has a 
significantly longer half-life compared to histone acetylation and phosphorylation, 
indicating the capacity of histone methylation to pass on parental epigenetic 
information in a noise-resistant manner. In contrast, histone acetylation and 
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phosphorylation are short-lived and thus not strictly viewed as true epigenetic marks93. 
Second, this histone modification has the ability to propagate to adjacent unmodified 
histones by directly and indirectly recruiting histone modifiers that write the same type 
of histone modification. As a well-studied example, H3K27me3 marks attract EED, which 
is one of the core components of Polycomb repressive complex 2 (PRC2) responsible for 
H3K27 trimethylation94. Considering the stability and self-enforcement of histone 
methylation, we investigated the effects of multiple histone methylation on osteoblast 
differentiation in MM patients as well as normal donors.  
The “Bivalent domain” discovered by Bernstein et al. in 2006 is a region on the 
genome harboring both the transcriptionally active H3K4me3 marks and the 
transcriptionally repressive H3K27 marks95. Although the opposing functions of 
H3K4me3 and H3K27me3 in the same genome appear to be contradictory at the first 
look, this epigenetic pattern allows fine-tuning of associated gene expression. By 
analogy, H3K4me3 functions as the “gas pedal” and H3K27me3 as the “brake pedal” in 
the scenario of gene expression. Genes with bivalent domains at their transcriptional 
start sites (TSSs), which are prevalent in embryonic stem cells (ESCs) and multipotent 
cells, are expressed at minimal levels95. Intriguingly, most of bivalent genes are 
transcription factors that dictate cell fates. Depending on the specific developmental 
cue, a bivalent domain may resolve to either a transcriptionally active domain by losing 
H3K27me3 or a transcriptionally silent domain by losing H3K4me395. Bernstein et al. also 
showed in a separate study that when mouse ESCs were induced to differentiate into 
neuronal progenitor cells (NPCs), 46% of bivalent domains resolved to H3K4me3 
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exclusively with induction of related genes. 16% of bivalent domains resolved to 
H3K27me3 exclusively and 32% lost both marks with silencing of related genes. The 
remaining 8% were unchanged96. Resolution of bivalent domains to monovalent 
domains was also observed during differentiation of mouse ESCs into mouse embryonic 
fibroblasts (MEFs)96. From the viewpoint of bivalent domains, a series of dichotomous 
decision commits ESCs to terminal differentiated lineages.  
The existence of a bivalent domain was equivocal since some argued that the 
detection by ChIP of both H3K4me3 and H3K27me3 at the same genomic region merely 
reflected cellular heterogeneity - a mixture of one population with H3K4me3 only and 
another with H3K27me3 only. These doubts were subsequently resolved thanks to the 
pioneering studies that utilized homogenous cell population97, single-cell technique98, or 
sequential ChIP99-102. In attempts to uncover “true” bivalency in certain genes, 
investigators had to take the necessary measures to minimize cellular heterogeneity. 
Further, mass spectrometry (MS) data suggest the coexistence of H3K4me3 and 
H3K27me3 in different H3 copies of the same nucleosome, with each mark occupying 
one H3 tail103,104. This asymmetric modification results from the ability of H3K4me3 or 
H3K27me3 to prevent methylation of the competing type on the same H3. Specifically, 
the presence of H3K27me3 destabilizes the interaction between H3 and H3K4 
methyltransferase complexes, thereby preventing establishment of new H3K4me3 
marks105. The existing H3K4me3 can be further removed from genes by KDM5A which is 
an H3K4me2/3 demethylase recruited by PRC2106. Similarly, H3K4me3 inhibits PRC2 
activity by abolishing the interaction of RbAp46/48 with H3107. MLL3/4 complexes, 
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which catalyze methylation of H3K4, contains the H3K27 demethylase UTX108,109. It’s 
interesting to see that a histone methyltransferase complex of one type generally 
associates with a histone demethylase of the competing type. In addition, active gene 
transcription facilitated by high levels of H3K4me3 removes H3K27me3 along the gene 
body as the elongating form of RNA Pol II binds the H3K27 demethylase JMJD3 and 
paves the way for productive transcription110.  
The antagonism between H3K4me3 and H3K27me3 delicately maintains the 
equilibrium between them in a bivalent domain until it’s severely disturbed in response 
to appropriate differentiation signals. Resolution of a bivalent domain to a monovalent 
domain is physiologically difficult to reverse since the accumulation of one type of 
methyl histone marks actively excludes the other type as discussed above. One 
exception involves induced pluripotent stem cells (iPSCs) where ectopic overexpression 
of the pluripotent transcription factors Oct4, Sox2, c-Myc and Klf4 restores bivalency 
that closely resembles ESCs111-113. Nevertheless, it doesn’t naturally occur in vivo. The 
relative irreversibility of a monovalent domain is consistent with the observation that 
ESCs progressively lose bivalent domains as they undergo terminal differentiation, 
although a few novel bivalent domains occasionally form.  
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1.4 Model Justification 
 
A. Osteoblast precursor model: 
MC4 cells together with other subclones were originally isolated by diluting 
phenotypically heterogeneous MC3T3-E1 cells at a density of 100 cells/100 mm dish and 
culturing them for 2 to 3 weeks until separate clones were well formed114. Compared to 
other subclones, MC4 cells show a strong potential to differentiate into mature 
osteoblasts in vitro after exposure to ascorbic acid for 12 days and inorganic phosphate 
for the last 2 days. They also produced woven bones over six weeks in Collagraft 
sponges implanted subcutaneously in immunodeficient mice. Some subclones able to 
mineralize in vitro nevertheless fail to form bones in vivo114. Alternatively, MC3T3-E1 
subclone 14 (MC14) displays a similar phenotype and can be used interchangeably with 
MC4 cells114. The close resemblance of MC4 cells to primary osteoblast precursors 
makes them an ideal candidate to study the molecular mechanisms of osteoblast 
differentiation under normal and pathological circumstances. Further, certain research 
questions can be answered using MC4 cells instead of primary BMSCs due to 
homogeneity of MC4 cells. In this study, investigating bivalent genes in MC4 cells 
maximally minimizes “apparent” bivalency simply generated by cellular heterogeneity. 
In contrast, investigating bivalent genes in primary BMSCs, the majority of which are 
nondifferentiating fibroblast-like cells115, inevitably makes the results difficult to 
interpret. In addition, examining changes in gene expression is more reliable in MC4 
cells since they aren’t masked by the presence of changes in other populations. 
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B. In vivo mouse model of MM: 
Aging C57BL/KalwRij mice spontaneously develop neoplasms of plasma cells, 
namely Waldenstrom macroglobulinemia and MM116-118. This unique feature provides a 
valuable reservoir of MM cells, known as the 5TMM series, to study MM and generate 
in vivo MM mouse models. Of the 5TMM series, 5T2MM and its more aggressive variant 
5T33MM lines have been extensively characterized119. The in vivo 5TMM models were 
successfully created by transplanting spontaneously developed myeloma cells in 
C57BL/KalwRij mice to syngeneic recipients, and propagated by continuously 
transplanting purified myeloma cells to mice.  The 5TMM model shows homing of 
myeloma cells specifically to bone marrow and the mice develop progressive bone 
destruction. The high similarity of the 5TMM model to MM patients allows it to be 
widely used in studies investigating homing and proliferation of myeloma cells117,120. 
However, it’s not an efficient model to study MMBD due to the extensive time (12-14 
weeks) required to develop bone lesions. The 5TGM1 model developed from the 5TMM 
model is better suited for research efforts investigating MMBD. 5TGM1 cells, derived 
from 5T33MM cells, cause severe bone destruction within 4 to 5 weeks in vivo121. In 
addition, we engineered 5TGM1 cells to stably express a fusion protein comprised of 
GFP and thymidine kinase (TK). GFP is used to monitor tumor burden and separate 
myeloma cells from other populations122. Since Ganciclovir, a guanine analog to treat 
cytomegalovirus (CMV) infection, is specifically phosphorylated by TK to form toxic 
metabolites, treating 5TGM1 cells with appropriate concentrations of GCV eliminates 
the MM without affecting other population123. In the 5TGM1 model, 5TGM1 cells are 
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injected into tibiae of C57BL/KalwRij mice to induce localized bone destruction. 
Comparable to the 5TMM model, the 5TGM1 model has tumor infiltration restricted to 
bone marrow and spleen when the cells are administrated intraveneously. What makes 
this model most appropriate is the rapidity of the development of lytic bone lesions and 
ability to isolate myeloma cells or BMSCs from inoculated bones. Other animal models 
of myeloma exist, including the Pristane-induced plasmacytoma in BALB/c mice, the 
SCID xenograft model and the SCID-hu model124. These models, however, present 
different characteristics from MM patients or are immunocompromised. As a result, we 
selected the 5TGM1 model to investigate the molecular mechanism(s) responsible for 
the long-term suppression of osteoblast differentiation in MM. 
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1.5 Rationale and Central Focus 
 
Studies characterizing MM-BMSCs have focused on their differences from those 
of normal donors, including microRNA profiles, gene profiles and biological phenotypes, 
and have provided important insights in how distinct gene profiles in MM-BMSCs 
contribute to their unique phenotype. Importantly, identification of these dysregulated 
microRNAs and genes provide valuable directions for future studies to understand the 
molecular mechanisms of OB differentiation. However, how ND-BMSCs gradually 
change into MM-BMSCs in MM patients and how this phenotype is maintained in the 
absence of myeloma cells is unclear. To address this research question, our studies 
could provide the evidence that epigenetic changes are implicated in the development 
of MM-BMSCs and long-term suppression of bone formation in MM.  
Activation of signaling cascades fade and allow cells to return to their previous 
states without continuous stimuli. However, development and adaption to the 
surrounding environment usually requires an organism to convert an ephemeral 
environmental signal into long-lived phenotypic changes. Epigenetic changes that 
control gene transcription independent of genetic sequence and are inheritable across 
generations act as a platform integrating all transient stimuli from outside of cells and 
establishing a stable phenotype accordingly125. Furthermore, the role of epigenetic 
changes in the pathogenesis of MMBD has not been clearly defined. In this study, we 
were interested in one particular epigenetic landscape known as bivalent domains. 
Besides its capacity of generating long-lasting epigenetic memory as discussed in the 
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previous section, emerging evidence provides hints of the possible involvement of 
bivalent domains in regulating osteoblast differentiation. The H3K4me3 demethylase 
nucleolar protein 66 (NO66)126 and retinoblastoma binding protein 2 (RBP2)127 exert 
inhibitory effects on osteoblast differentiation. Ectopic expression of EZH2, which 
mediates H3K27 tri-methylation, impairs osteogenesis while enhancing lipogenesis128. 
Based on these findings, we hypothesized that bivalent domains dictate the expression 
of genes essential for osteoblast differentiation and that resolution of bivalent domains 
into transcriptionally silent domains mediates the long-term suppression of osteoblast 
differentiation in MM by silencing the expression of these key regulators. Understanding 
the molecular mechanism(s) should help identify targets to reverse MMBD and possibly 
decrease tumor burden. The proposed mechanism may also be generalizable to other 
biological phenomena where an ephemeral microenvironment persistently changes 
phenotypes of cells, such as hematopoietic stem cell (HSC) development in different 
organs during embryogenesis and the establishment of latent viral infection in host cells. 
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CHAPTER 2 
 MATERIALS AND METHODS 
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2.1 Chemicals and Antibodies  
 
JNK inhibitor SP600125 (Cat # S5567), p38 inhibitor SB203580 (Cat # S8307) and 
MEK1 inhibitor PD98059 (Cat # S215) were purchased from Sigma. Antibodies to JMJD3 
(1:250), H3K27me3 (1:3000) and NF-kB inhibitor (Cat # 481406) were purchased from 
Millipore. Runx2 (1:1000,), phospho-c-Jun (1:1000), c-Jun (1:1000), IkBa (1:1000) were 
obtained from Cell Signaling, and b-actin (1:3000) from Santa Cruz. 
 
2.2 Plasmids 
 
Cumate-pLenti-Cloning-SV40-GFP (Cat: # iCu007, Abmgood) (Figure 2-1); MGC 
premier cDNA clone for JMJD3 (Cat: # TCMS1004, Transomic); psRSV-Rev (Cat: # 12253, 
Addgene); pMDLg-RRE (Cat: # 12251, Addgene); pCMV-VSVG (Cat: # 8454, Addgene); 
Gfi1-overexpressing pcDNA 3.1 was constructed by former lab member.  
 
2.3 Buffers 
 
Radioimmunoprecipitation assay (RIPA) buffer: 150 mM sodium chloride, 1.0% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris (pH 8.0); 2x Laemmli buffer: 
10% b-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 4% SDS and 0.125 M 
Tris-HCl;  Running Buffer for Western blot: 190 mM glycine, 25 mM Tris and 0.1% SDS; 
Transfer buffer for Western blot: 192mM glycine, 20% methanol, 25 mM Tris and 0.1% 
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SDS; Tris-buffered saline with Tween 20 (TBST) buffer: 150 mM sodium chloride, 0.1% 
Tween 20 and 20 mM Tris (pH 7.5); Stripping Buffer: 25 mM glycine and 2% SDS (pH 2.0); 
Tris-borate-EDTA (TBE) buffer: 89mM boric acid, 2mM EDTA and 89 mM Tris (pH 7.6). 
 
2.4 Cell Line Culture 
 
Mouse MC3T3-E1 subclone-4 (MC4) pre-osteoblasts were purchased from 
American Type Culture Collection (ATCC) and maintained in ascorbic acid-free α-
modified Eagle medium (α-MEM) (Cat: # A1049001, GIBCO) supplemented with 10% FCS 
and 1% pen/strep. MC4 cells were continuously sub-cultured twice a week in a ratio of 
1:6 using trypsin-EDTA solution (Cat: # T4049, Sigma) until they reached passage 20. 
Osteoblast differentiation was induced by culturing confluent MC4 cells in α-MEM 
containing 10% FCS, 50 µg/ml ascorbic acid and 10 mM b-glycerophosphate.  
The mouse myeloma cell line 5TGM1 was kindly provided by Dr. Bobatunde O. 
Oyajobi (University of Texas at San Antonio) and the late Gregory R. Mundy (Vanderbilt 
University, Nashville, TN). These MM cells can be propagated in vitro, home to the BM 
to induce osteolytic lesions, secrete IgG2b, and produce the same panel of cytokines 
associated with MM bone disease in patients. 5TGM1 cells were stably transfected with 
a lentiviral construct containing a fusion gene encoding GFP for positive selection and 
thymidine kinase (TK) for negative selection. The construct to produce these engineered 
5TGM1 cells (5TGM1-GFP-TK) was kindly provided by Dr. Hee-Yong Chung (Hanyang 
University, Seoul, Korea). 5TGM1 cells were maintained in RPMI 1640 (Cat: # GIBCO) 
27 
with 10% FCS and 1% pen/strep, and sub-cultured twice a week in a ratio of 1: 10. Co-
cultures of 5TGM1 and MC4 cells (10:1) were performed in a 1:1 (v/v) mix of α-MEM 
and RPMI 1640 with 10% FCS. 
The human embryonic kidney cell line (293TF) was purchased from Invitrogen 
and maintained in Dulbecco's modified Eagle's Minimum Essential Medium (DMEM) (Cat: 
# 12200-017, GIBCO) with 10% FBS and 1% pen/strep. 293TF cells were sub-cultured 
three times a week in a ratio of 1:8 to avoid any confluency. Alternatively, 293TF cells 
were cultured in DMEM with 10% FBS only for any transfection experiments. 
 
2.5 Primary Human BMSC Culture 
 
After obtaining informed consent in accordance with the Declaration of Helsinki 
and approval by Indiana University Institutional Review Board, BM aspirates were 
collected in heparin from 4 healthy donors and 7 myeloma patients. Marrow 
mononuclear cells were separated by Ficoll-Hypaque density sedimentation and 
cultured in for 3 weeks to obtain stromal cells as follows. Briefly, BM cells were 
incubated in Iscove’s Modified Dulbecco’s Medium (IMDM) (Cat: # 12200-036, GIBCO) 
with 10% FCS and 1% pen/strep overnight, and the nonadherent cells were removed the 
next day. The cultures were then continued for 21 days with media changes every 4 
days. Cells were subsequently detached with trypsin-EDTA solution at subconfluence 
and replated (105 cells/10 cm dish) for use at passages 2 and 3. 
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2.6 Mouse Model of MMBD 
 
Specific-pathogen-free C57BL/KaLwRij mice (6–12 weeks of age) were obtained 
from Dr. Jolene Windle at Virginia Commonwealth University. The knees of mice were 
bent over to expose the epiphysis of tibiae, where a needle was inserted along the long 
axis of tibiae to inject 20 µL of saline with or without 105 5TGM1 cells. Blood samples 
were collected once a week for ELISA assay of monoclonal IgG2b secreted by MM cells. 
Mice were sacrificed 21 days after tumor inoculation. The severity of bone destruction 
was initially assessed by X-ray radiography and subsequently quantified by microCT. All 
research protocols were approved by the Veterans Administration Indianapolis 
Healthcare System and IUSM Institutional Animal Care and Use Committee.  
Primary BM cells were flushed out of tibiae using 1 ml of IMEM with 1% 
pen/strep. The cells were centrifuged, resuspended and plated in 100 mm culture dishes 
in 10 mL IMEM supplemented with 10% FCS and 1% pen/strep. Nonadherent cells were 
removed the next day and the media replaced every other day. Cell cultures were 
treated with 20 µg/ml ganciclovir for 3 days to remove residual 5TGM1-GFP-TK cells. 
Adherent BMSCs were cultured at 37°C for 21 days and then sub-cultured to passage 2 
and 3 using trypsin-EDTA before their expression profile and differentiation potential 
were assessed. 
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2.7 JMJD3 siRNA Transfection of MC4 Cells  
 
Each transfection experiment included scrambled siRNA (Cat: # D-001810-10-05, 
Dharmacon) as a negative control, mouse GAPDH siRNA (D-001830-02-05, Dharmacon) 
as a positive control and two different sets of mouse JMJD3 siRNAs (Cat: # J-063799-09-
0002 and J-063799-10-0002, Dharmacon). These mouse JMJD3 siRNAs were modified to 
minimize off-target effects and specifically targeted two different open reading frames 
(ORFs) of JMJD3. MC4 cells were seeded in 6-well plates at a density of 8 X 104 cells/well 
in the afternoon so that they reached desired 80% confluency after overnight culture. 
For each well, one tube with 200 µl of reduced serum medium Opti-MEM I (Cat: # 
31985-062, Thermofisher Scientific) containing 0.5 µl of 100 µM siRNA and another tube 
with 200 µl of serum-free Opti-MEM containing 3 µl of DharmaFECTtm 1 transfection 
reagent (T-2001-02) were prepared. Depending on the number of wells to be 
transfected and the number of siRNAs to be used, the volume of each component was 
accordingly scaled up. Each tube was incubated at room temperature for 5 minutes. The 
two tubes were then mixed together and incubated for additional 20 minutes.  1.6 ml of 
antibiotic-free complete medium was then added to the mix for a final volume of 2 ml 
transfection medium and a final siRNA concentration of 25 nM.  The culture media in 6-
well plates were replaced by the freshly made transfection medium, which was 
removed 6 hours later to avoid the cytotoxicity of the DharmaFECTtm 1 transfection 
reagent to MC4 cells. RNA and protein levels were examined 48 hours later to 
determine knockdown efficiency by qPCR and Western blot, respectively.
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2.8 Transient Transfection 
 
Cells were seeded in 6-well plates in a density of 8 X 104 cells/well for MC4 cells 
and 1 X 106 cells/well for 293TF cells in the afternoon so that they reached desired 80% 
confluency after overnight culture. For each well, 6 ul of Fugene 6 transfection reagent 
(Cat: # E2691, Promega) was gently diluted in 94 ul of Opti-MEM and incubated in room 
temperature for 5 minutes. 1 µg plasmid DNA was added to obtain the transfection 
reagent / DNA mix, which was incubated for additional 20 minutes and then added in a 
drop-wise manner to each well containing complete culture medium. Depending on the 
number of wells to be transfected and the number of plasmids to be used, the volume 
of each component was accordingly scaled up. The medium was replaced 6 hours later 
to avoid any cytotoxicity of Fugene 6 transfection reagent to MC4 cells. Cells were 
visualized under a fluorescent microscope to assess transfection efficiency, if 
transfected with plasmids that express GFP or RFP. RNA and protein levels were 
examined 48 hours later by qPCR and Western, respectively. 
 
2.9 Generation of a Stable JMJD3-Overexpressing Cell Line  
 
A third-generation lentiviral system was used to package a self-constructed 
mouse JMJD3-overexpressing plasmid (vJMJD3) or empty plasmid (vControl) since 5’ 
long-terminal repeat (LTR) of its backbone is hybrid with a CMV promoter, which 
doesn’t require Tat to transcriptionally activate the gene of interest.  Further, splitting of 
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the lentiviral products into three different vectors maximally prevents generation of 
replication-competent lentiviruses. To produce the viral soup, 293TF cells were seeded 
in 10 cm dishes at a density of 6 X 106 cells/dish in the afternoon so that they reached 
the desired 80% confluency the following morning. Transient transfection was 
performed as described above except multiple plasmid DNAs were transfected 
simultaneously. Briefly, the transfection reagent / plasmid DNA mix containing 534 µl of 
Opti-MEM I, 66 µl of Fugene 6, 6.5 µg pMDLg-RRE, 3.5 µg psRSV-Rev, 2.5 µg pCMV-
VSVG, and 10 µg vJMJD3 or vControl were added in a drop-wise manner to 293TF cells 
with 10 ml complete medium. The medium was then replaced 6 hours later. The viral 
soup was collected 48 hours later and centrifuged at 1500 RPM to collect the 
supernatant, which was immediately stored in a -80 °C freezer for future use.  
MC4 cells were seeded in 6-well plates at a density of 8 X 104 cells/well in the 
afternoon so that they reached desired 80% confluency the following morning. The 
complete medium was replaced by viral soup containing 2 µg/ml polybrene that 
facilitated the attachment of viral particles to cell surface. The viral soup was then 
replaced by complete medium 24 hours later. 48 hours after infection, stable JMJD3-
overexpressing MC4 cells (MC4/JMJD3) or their empty vector control counterparts 
(MC4/EV) were selected by consecutive 3-week culture in complete medium containing 
2 µg/ml puromycin, the concentration of which was experimentally determined by 
killing curves. The success of generating MC4/JMJD3 and MC4/EV cells was validated by 
comparing JMJD3 mRNA and protein levels. 
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2.10 Full-length Mouse JMJD3 cDNA Synthesis 
 
In a total reaction volume of 25 µl, 12.5 of µl Q5 High-Fidelity 2X Master Mix (Cat: 
#M0492S, NEB), 10 mM mouse JMJD3 forward primer (Appendix), 10 mM mouse JMJD3 
reverse primer (Appendix), 1 ng MGC premier cDNA clone for JMJD3 and variable 
volume of nuclease-free water were gently mixed and prepared on ice. Routine PCR was 
subsequently performed using the following thermocycling conditions: 1 cycle at 98 °C 
for 30 seconds, followed by 30 cycles of 98 °C for 10 seconds and 78 °C for 3 minutes, 
and finally 1 cycle at 72 °C for 2 minutes. The correct size of PCR products was validated 
by DNA electrophoresis.  
 
2.11 Purification of cDNA and Plasmids 
 
JMJD3 cDNA products and endonuclease-digested plasmids were purified using 
QIAquick PCR purification Kit (Cat: # 28104, Qiagen) according to the manufacturer’s 
instructions. Briefly, 1 volume of each sample and 5 volumes of Buffer PB were gently 
mixed and transferred to a QIAquick column. The QIAquick column was centrifuged at 
12000 RPM and the flow-through discarded after every procedure. The DNA retained on 
the column membrane was then washed once with 750 µl of Buffer PE, followed by 
elution using 30 µl of nuclease-free water. 
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2.12 Cloning of Mouse JMJD3 cDNA into Cumate-pLenti-Cloning-SV40-GFP Lentiviral 
Plasmid 
 
Purified mouse JMJD3 cDNA and Cumate-pLenti-Cloning-SV40-GFP plasmid were 
digested by MfeI (Cat: # R0589S, NEB) and BamHI (Cat: # R0136T, NEB). The reaction mix 
of 50 µl containing 1 µg DNA, 10 units of MfeI, 10 units of BamHI, 5 µl of 10X CutSmart 
Buffer, and variable volumes of nuclease-free water was incubated at 37 °C for 3 hours. 
The desired DNA fragments were isolated by subjecting digested DNA samples to DNA 
electrophoresis and cutting out the bands of correct size. These DNA fragments were 
then purified using a QIAquick Gel Extraction Kit (Cat: # 28704, Qiagen) according to the 
manufacturer’s instructions. Mouse JMJD3 cDNA fragments and the Cumate-pLenti-
Cloning-SV40-GFP backbone were ligated at room temperature for 10 minutes in a 
reaction volume of 20 µl containing 2 µl of T4 DNA ligase Buffer (10X), 84.67 ng mouse 
JMJD3 cDNA, 50 ng vector, 1 µl of T4 DNA Ligase (Cat: # M0202, NEB) and variable 
volume of nuclease-free water. 
 
2.13 Transformation into 5-alpha Competent E. coli 
 
100 ng of plasmid DNA was gently mixed with 50 µl of freshly thawed 5-alpha 
competent E. coli (Cat: # C2987H, NEB). The mix was incubated on ice for 30 minutes, 
followed by heat shock at 42 °C for 30 seconds. 950 µl of room temperature LB medium 
was then added. The transformed bacteria were then vigorously shaken at 37 °C for 60 
34 
minutes and 50 µl was spread on a neomycin-containing LB plate for overnight culture. 
The desired clone was subsequently validated based on DNA electrophoresis and 
plasmid sequencing results. 
 
2.14 Minipreparation of Plasmids 
 
Minipreparation of plasmids was done using a QIAprep Spin Miniprep Kit (Cat: # 
27104, Qiagen) according to the manufacturer’s instructions. The obtained plasmids 
were mainly used for cloning and validation. Briefly, 2.5 ml of bacteria in LB medium 
were pelleted by centrifugation at 8000 RPM for 3 minutes at room temperature and 
resuspended in 250 µl of prechilled Buffer P1 by vigorous vortex. 250 µl of Buffer P2 was 
mixed with the resuspended bacteria by inverting microcentrifuge tubes several times 
until the solution becomes blue. 350 µl of Buffer N3 was then added with solution 
turning colorless and white precipitates forming. Following centrifugation at 13000 RPM 
for 10 minutes, the supernatant was transferred to the QIAprep 2.0 spin column. 
Columns were centrifuged at 13000 RPM for 30 seconds and flow-through discarded 
after each procedure. The plasmids retained on the columns were washed with 750 µl 
of Buffer PE and subsequently eluted with 50 µl of Buffer EB. Plasmids were 
immediately used or stored at -20 °C. 
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2.15 Maxipreparation of Plasmids 
 
Minipreparation of plasmids was done using QIAfilter Plasmid Maxi Kit (Cat: # 
12262, Qiagen) according to the manufacturer’s instructions. The obtained plasmids 
were mainly used for transient and stable transfections. Briefly, 250 ml of bacteria in LB 
medium were pelleted by centrifugation at 6000 x g for 15 minutes at 4 °C and 
resuspended in 10 ml of prechilled Buffer P1 by a combination of repetitive pipetting 
and vigorous vortex. 10 ml of Buffer P2 was mixed with the resuspended bacteria by 
inverting the microcentrifuge tubes 4 to 6 times until the solution becomes blue. 10 ml 
of Buffer N3 was then added with solution turning colorless and white precipitates 
forming. The bacterial lysate was then transferred to the QIAfilter Cartridge and filtered 
through the membrane of the cartridge into the equilibrated QIAGEN-tip with 
precipitates left behind. The bacterial lysate went through the resin of QIAGEN-tip by 
gravity. The QIAGEN-tip was then washed with 30 ml of Buffer QC twice. Plasmids were 
eluted into 15 ml of Buffer QF, and, after thoroughly being mixed with 10.5 ml of room-
temperature isopropanol, were centrifuged at 15000 x g for 30 minutes at 4 °C. 
Obtained plasmid precipitates were rinsed with 5 ml of room-temperature 70% ethanol, 
air-dried for 10 minutes, and dissolved into TE buffer.  
 
2.16 DNA Electrophoresis 
 
12 µl of DNA samples were thoroughly mixed with 3 µl of GelPilot Loading Dye 
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(5X) (Cat: # 239901, Qiagen) and loaded onto 0.8% of agarose gel. 6 µl of GelPilot 1kb 
Ladder (Cat: # 239085, Qiagen) was also used to determine band sizes. DNA 
electrophoresis was conducted at 80 V for 40 minutes, followed by imaging under UV 
light.  
 
2.17 RNA Extraction, RNA Quantification, cDNA Synthesis and qPCR 
 
RNA extraction was performed using an RNeasy Mini Kit (Cat: # 74104, Qiagen) 
according to the manufacturer’s instructions. Briefly, cells were washed with cold PBS 
twice to remove any residual medium before they were lysed by adding 350 µl of Buffer 
RLT Lysis buffer to each sample and homogenized by pipetting up and down. Cell lysates 
were then transferred to columns that have silicon membranes to selectively bind RNA. 
Columns were centrifuged at 12000 RPM at room temperature and flow-through 
discarded after each procedure.  The columns were washed with 750 µl of Buffer RW1 
once followed by 500 µl of Buffer RPE twice. The RNA retained in the column was then 
eluted with 50 µl of nuclease-free water.  
The concentration and quality of RNA were determined using a NanoDrop 2000 
Spectrophotometer after RNA extraction. All RNA samples were kept on ice the entire 
time. 1 µl of nuclease-free water was first assessed as blank before 1 µl of each RNA 
sample was quantified. Only RNA samples with A260/A230 and A260/A280 ratios above 
1.8 were used in subsequent application. After obtaining their concentration, RNA 
samples were immediately used for cDNA synthesis or stored at -80 °C. 
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cDNA synthesis was performed using the two-step method. All reactions were 
assembled on an ice-cold plate. In the first reaction volume of 2.5 µl, 300 ng RNA, 0.25 
µg random primers (Cat: # C118A, Promega) and nuclease-free water were thoroughly 
mixed, heated at 70 °C for 5 minutes and immediately chilled on ice. 7.5 µl of reverse 
transcription reaction mix per sample was prepared at the same time. Depending on the 
number of samples, the volume of each ingredient was accordingly scaled up. For each 
sample, the reverse transcription reaction mix contained 2 µl of GoScript 5X Reaction 
Buffer (Cat: # A500D, Promega), 1.5 µl of 25 mM MgCl2 (Cat: # A351H, Promega), 0.5 µl 
of 10 mM PCR Nucleotide Mix (Cat: # U151B, Promega), 0.5 µl of GoScript Reverse 
Transcriptase (Cat: # A501D) and variable amount of nuclease-free water. 2.5 µl of 
RNA/primer mix and 7.5 µl of reverse transcription mix were combined and incubated in 
a T100 Thermal Cycler (Biorad) using the following thermocycling conditions: 25 °C for 5 
minutes, 42 °C for 1 hour and 70 °C for 15 minutes. cDNA samples were diluted by 10 
folds. They were then immediately used for qPCR quantification or stored at -20 °C. 
CFX96 Touch System (Biorad) was utilized for qPCR operation. For each reaction, 
5 µl of SsoAdvanced universal SYBR Green supermix (Cat: # 1725274, Biorad) containing 
500 nM of forward and reverse primers, and 5 µl of diluted cDNA sample were mixed 
thoroughly. Technical triplicates were carried for each gene/cDNA sample combination 
to minimize variability. The reaction conditions were as follows: 1 cycle of 95 °C for 30 
seconds, followed by 35 cycles of 95 °C for 10 seconds and 60 °C for 30 seconds, and 
finally the melting-curve analysis embedded in the program.  The DNA sequences of 
mouse and human primers used for qPCR are listed in Appendix. Relative expression 
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was calculated using the comparative 2−ΔΔCt method. The geometric means of CT values 
of b-actin, GAPDH and HMBS were used as the internal control since a combinational 
application of these three genes provide the most reliable control in osteoblasts based 
on the geNorm algorithm.  
 
2.18 Protein Extraction and Quantification 
 
Cells were washed with cold PBS twice to remove any residual medium before 
adding an appropriate volume of RIPA buffer freshly supplemented with 1 mM PMSF 
(Cat: # 329-98-6, Sigma) and protease inhibitor cocktail (Cat: # P8340, Sigma). Cell 
lysates were collected into 1.7 ml microcentrifuge tubes using cell scrapers, incubated 
on ice for 30 minutes and centrifuged at 12000 RPM for 20 minutes at 4 °C. The 
supernatants, which were the protein sample free from any cellular debris, were then 
transferred to new 1.7 ml microcentrifuge tubes. 
Protein concentrations were determined using a Pierce BCA Protein Assay Kit 
(Cat: # 23225, ThermoFisher Scientific) according to the manufacturer’s instructions. 
Briefly, protein standards were prepared by serial dilution of BSA. Final BSA 
concentrations of protein standards included 0 µg/µl, 0.33 µg/µl, 0.5 µg/µl, 0.66 µg/µl, 
0.83 µg/µl, 1 µg/µl and 2 µg/µl. 15 µl of each protein standard were added in order to a 
96-well plate based on their concentrations. 2.5 µl of protein samples diluted with 12.5 
µl of MilliQ water were added to the same 96-well plate. Protein concentrations were 
measured using SpectraMax 250. The coefficient of determination (R2) of protein 
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standards was also checked to ensure accuracy. After obtaining protein concentrations, 
protein samples were immediately denatured for Western blot or stored at -80 °C.  
 
2.19 Western Blot and Analysis 
 
15 µg of protein thoroughly mixed with 4X Laemmli Sample Buffer were heated 
at 95 °C for 5 minutes before being loaded into wells of 4-20 % Mini-PROTEAN TGX 
precast protein gels (Cat: # 4561095, Biorad). Precision Plus Protein Standards (Cat: # 
1610375, Biorad) were used to indicate band size. The gel was run at 80 V for 10 
minutes and 100 V for approximately 90 minutes. 
Protein transfer was performed using the semi-dry method. From bottom (anode) 
to top (cathode) were a thick filter paper, a PVSF membrane having been activated by 
methanol for 1 minute, the gel and a thick filter paper. The protein transfer conditions 
were 12 V for 20 to 30 minutes, depending on the size of the protein of interest. 17 kD 
histone proteins require shorter transfer time to prevent any penetration through the 
PVSF membrane. 178 kD JMJD3 requires a longer time for complete transfer.  
The PVSF membrane was then blocked in 5% (w/v) skim milk in TBST at room 
temperature for 1 hour, followed by overnight incubation with primary antibodies in 
their proper blocking solution at 4 °C. On the following day, the PVSF membrane was 
rinsed with TBST 3 times for 10 minutes each. HRP-conjugated secondary antibodies 
diluted in 2% skim milk in TBST were incubated with the PVSF membrane for 1 hour at 
room temperature. The PVSF membrane again was rinsed with TBST 3 times. Protein 
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signals were visualized using chemiluminescent substrates (Cat: # RPN2232, GE 
Healthcare). The ratio of protein of the interest to the internal control was semi-
quantitatively determined by ImageJ software.  
 
2.20 Chromatin Immunoprecipitation 
 
ChIP assay was performed using the SimpleChIP Enzymatic Chromatin IP Kit (Cat: 
#9003, Cell Signaling) according to manufacturer’s instruction. The kit utilized 
micrococcal nuclease digestion instead of sonication to generate DNA fragments of 
approximately 150-900 bp. 8 X 106 treated or untreated MC4 cells were lysed for each 
cross-linked chromatin preparation that sufficed for 5 separate immunoprecipitations.  
Protein and DNA were cross-linked by incubating the cells in 1% (v/v) formalin 
for 10 minutes. The cross-linking was subsequently stopped by addition of 1/10 volume 
of 10X glycine. Cells were washed with ice-cold PBS twice, transferred into a 15 ml 
conical tube in ice-cold PBS plus PMSF, and centrifuged at 1500 RPM at 4 °C for 5 
minutes to obtain the cell pellets. To selectively lyse plasma membranes, the pellets 
were incubated in 10 ml of ice-cold Buffer A supplemented with DTT, protease inhibitor 
cocktail and PMSF on ice for 10 minutes. Nuclei were then centrifuged and resuspended 
in 1 ml Buffer B plus DTT, which provided chemical conditions for micrococcal nuclease 
to subsequently digest DNA at 37 °C for 20 minutes. The volume of micrococcal nuclease 
used was experimentally optimized by visualizing DNA fragments on agarose gel 
following DNA electrophoresis. Nuclear pellets were then sonicated by three 20-second 
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pulses on ice to break the nuclear membrane. The resulting lysates were centrifuged at 
10000 RPM for 10 minutes at 4 °C to obtain the supernatants, which were the cross-
linked chromatin preparation that could be stored at -80 °C for future use.  
For each immunoprecipitation, 400 µl of 1X ChIP Buffer freshly supplemented 
with 2 µl of protease inhibitor cocktail were thoroughly mixed with 100 µl of the cross-
linked chromatin preparation. The volume of each component was scaled up 
accordingly depending on the number of immunoprecipitaions to be done.  10 µl of the 
mix was set aside as 2% input, while the rest was incubated with 10 µl of H3 antibody 
(Cat: # 4620S, Cell Signaling) as a positive control, 2 µl of normal rabbit IgG (Cat: # 2729, 
Cell Signaling) as a negative control, 2 µl of H3K27me3 antibody (Cat: # 07-449, 
Millipore), or 2 µl of H3K4me3 antibody (Cat: # ab8580, Abcam) overnight at 4 °C.  
The following day, each immunoprecipitation preparation was incubated with 30 
µl of ChIP-Grade Protein G Agarose Beads for 2 hours at 4 °C with rotation. The agarose 
beads having sequestered the DNA-protein complexes were pelleted at 6000 RPM for 1 
minute and supernatant discarded. They were rinsed with 1 ml of Low Salt Wash Buffer 
(300 µl 10X ChIP buffer + 2.7 ml water) at 4 °C for 5 minutes three times followed by 1 
ml of High Salt Wash Buffer (100 µl 10X ChIP Buffer + 900 µl water + 70 µl 5M NaCl) at 
4 °C for 5 minutes once. DNA-protein complexes were eluted by incubating agarose 
beads in 150 µl 1X ChIP Elution Buffer for 30 minutes at 65 °C with gentle vortexing. 
After the agarose beads were removed by brief centrifugation at 6000 RPM for 1 minute, 
the cross-linking of DNA-protein complexes was reversed by adding 6 µl 5M NaCl and 2 
µl Proteinase K to the supernatant, and incubating for 2 hour at 65 °C. The spared 2% 
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input was also diluted with 150 µl of 1X ChIP Elution Buffer and treated identically with 
6 µl 5M NaCl and 2 µl Proteinase K as described above to reverse DNA-protein 
crosslinking. 
Eluted DNA was purified using the provided DNA purification spin columns. 
Briefly, 150 µl of DNA sample thoroughly mixed with 600 µl of DNA Binding Reagent A 
was transferred to the columns and centrifuged at 14000 RPM for 30 seconds. The DNA 
retained in the column was subsequently washed with 700 µl of DNA Wash Reagent B 
and eluted into 1.7 ml microcentrifuge tubes with 50 µl of DNA Elution Reagent C.  
Purified DNA from immunoprecipitation preparations and 2% input was then analyzed 
by qPCR using primers that specifically targeted the mouse Runx2 and Osterix 
promoters (Appendix). The reagents and thermocycling conditions were the same as 
those for standard qPCR. The immunoprecipitation efficiency was calculated using the 
following formula: Percent Input = 2% X 2(CT 2% Input Sample – CT IP Sample) 
 
2.21 ALP Staining 
 
One BCIP/NBT tablet (Cat: # B5655, Sigma) was dissolved in 10 ml of distilled 
water to prepare the substrate solution. Cells were then washed with ice-cold PBS twice 
to remove any residual medium, followed by short incubation in 10% neutral buffered 
formalin (v/v) for 30 seconds. Longer fixation led to irreversible inactivation of ALP. Cells 
were washed with ice-cold PBS freshly supplemented with 0.05% Tween 20 twice before 
incubation in the substrate solution in the dark for 10 to 20 minutes. The staining 
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process was checked every 5 minutes to prevent saturation. Staining was stopped by 
removing the substrate solution and rinsing the cells with ice-cold PBS supplemented 
with 0.05% Tween 20. 
 
2.22 Alizarin Red Staining 
 
To prepare the Alizarin Red S solution, 2 g Alizarin Red S (Cat: # A5533, Sigma) 
was dissolved in 100 ml of distilled water with the pH adjusted to 4.1 to 4.3 using HCl or 
NH4OH. The solution was filtered and stored in the dark at room temperature. The pH 
was checked every time before staining. Cells were washed with ice-cold PBS twice to 
remove any residual medium, followed by incubation in 70% ethanol overnight. Cells 
were washed with distilled water twice before being incubated in the Alizarin Red S 
solution at room temperature in the dark for 45 minutes. The staining process was 
stopped by removing the Alizarin Red S solution and rinsing the cells with distilled water 
four times. 
 
2.23 MTT Assay 
 
10 µl of 5 mg/ml MTT (3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium 
Bromide) (Cat: # M2128, Sigma) dissolved in distilled water was added to only 100 µl of 
complete medium as control or cells in 100 µl of complete medium in a 96-well plate. 
After incubation of the plate at 37 °C for 4 hours, 100 µl of MTT lysis buffer (10% SDS 
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plus 0.01 M HCl) was added to each well. On the following day, the plate was read using 
the SpectraMax 250 at a wavelength of 570 nm.  
 
2.24 Statistics 
 
Each experiment was repeated at least 3 times, and all quantitative data are 
presented as mean ± SD. Statistical significance was determined by unpaired two-tailed 
Student t test if two groups were compared or one-way ANOVA if more than two groups 
were involved.  Results were considered significantly different for p < .05. The number 
of * marks was used in the figures to indicate the p value range with * < 0.05, ** < 0.01, 
*** < 0.001. 
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Figure 2: Plasmid Map of iCumate-pLenti-Cloning-SV40-GFP Backbone 
 
MfeI and BamHI multiple cloning sites (MCSs) were selected for insertion of the full-
length mouse JMJD3 due to the absence of these recognized restriction sites in the 
JMJD3 sequence. The expression of JMJD3 is driven by a hybrid CMV promoter (yellow 
box). A kanamycin resistance gene (orange box) is expressed for positive selection of 
bacterial clones cultured on LB plates containing 50 µg/ml kanamycin. Puromycin 
resistance gene (light blue box) is expressed under a SV40 promoter (dark blue box) for 
positive selection of MC4 cell clones cultured in complete medium containing 2 µg/ml 
puromycin. GFP is expressed for visual assessment of infection efficiency and positive 
selection by FACS.  
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CHAPTER 3 
DOWNREGULATION OF THE H3K27ME3 DEMETHYLASE JMJD3 ALLOWS RESOLUTION 
OF THE BIVALENT DOMAINS ON THE RUNX2 AND OSTERIX PROMOTERS AND 
CONTRIBUTES TO THE INHIBITION OF OSTEOBLAST DIFFERENTIATION IN MM 
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3.1 Introduction 
 
Multipotent BMSCs possess the capacity to differentiate into osteoblasts, 
chondrocytes, adipocytes, and myoblasts in response to appropriate stimuli. The 
differentiation process is initiated by induction of a set of pivotal transcription factors 
that activate the expression of lineage-specific genes and suppress the expression of 
transcription factors essential for other differentiation processes. Runx2 and Osterix 
direct BMSCs to osteoblast differentiation80,81,129; Sox5/6/9 regulates chondrocyte 
differentiation130,131; PPARg132, C/EBPa133 and KLF15134 dictate adipocyte differentiation; 
and MyoD5135, Myf5135 and myogenin136 drive myogenesis. Dysregulation of these 
transcription factors have been reported in a variety of diseases.  
Runx2 belongs to the Runx family of transcription factors that share a DNA-
binding runx domain and, when forming a heterodimer with Cbfb, binds to its consensus 
sequence 5’-PYGPYGGT-3’137. Runx2 induces the expression of Osterix, ALP, COL1a1, 
SPP1, BGLAP, and IBSP81,138. These target genes either play an important role in 
osteoblastogenesis or are integral components of the bone mineralized matrix.  
Compared to wild-type mouse embryos, homozygous Runx2 -/- embryos manifest a 
complete lack of skeletal ossification due to defective endochondral and 
intramembranous ossification. Cartilage development, however, is unaffected80,129. 
Consistent with in vivo studies, calvarial cells isolated from Runx2 -/- mice fail to 
differentiate into osteoblasts in response to BMP2 treatment. They retain the capacity 
to differentiate into mature adipocytes and chondrocytes139. Osterix is equally 
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important as Runx2 and is another master transcription factor of osteoblast 
differentiation. Osterix -/- mouse embryos closely resemble the phenotype of Runx2 -/- 
mouse embryos with absent mineralization, even though Runx2 is normally expressed in 
osterix -/- mice81.  
In addition to transcription factors, normal osteoblast differentiation requires 
ongoing epigenetic remodeling of the chromatin landscape140-144. Epigenetic 
mechanisms modulate the accessibility of osteoblast-specific genes to transcriptional 
activators and repressors, thereby regulating gene expression independent of DNA 
sequences. Considering the longevity and inheritability of “true” epigenetic marks, any 
anomaly of epigenetic modifiers that write or erase these marks may fundamentally 
disrupt osteoblast differentiation long term, as occurs in MM.  MM patients present 
with lytic bone lesions that persist even after they are in complete remission following 
treatment. Further, BMSCs isolated from MM patients show an impaired capacity to 
differentiate into functional osteoblasts compared to those from normal donors52-55. 
These defects persist after myeloma cells are removed. Chromosomal alterations and 
genetic mutations have been sporadically described in BMSCs from MM patients, and 
these alterations/mutations have failed to explain the persistent blockade of osteoblast 
differentiation63. Therefore, it’s reasonable to infer that epigenetic changes are 
potentially involved in the long-term suppression of osteoblast differentiation in MM. In 
our studies, we focused on histone methylations, H3K4me3 and H3K27me3, to explain 
osteoblast suppression in MM due to their role in generating epigenetic memory as 
discussed in details in Chapter 1.4. In support of this notion, bivalent domains, defined 
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by co-occupancy of both H3K4me3 and H3K27me3 marks at the same loci, are enriched 
on promoters of developmentally important genes in ESCs and cells of limited potency95. 
Resolution of bivalent domains into either transcriptionally active or repressive domains 
determines lineage specification96. Emerging evidence has shown that the histone 
modifiers of H3K4me3 or H3K27me3 regulate osteoblast differentiation. However, 
which osteobastogenic genes are occupied by bivalent domains at their TSSs has not 
been identified. Due to the essential role of Runx2 and Osterix in osteoblast 
differentiation, we first investigated the histone methylation pattern of their promoters 
by ChIP.  
Trithorax group (trxG) and Polycomb group (PcG) proteins are two antagonistic 
systems involved in establishing and maintaining bivalency145. They were initially 
discovered as a heterogeneous collection of proteins whose mutations disrupt Hox gene 
expression pattern and proper body segmentation in drosophila. A subset of trxG 
proteins assist gene transcription by spreading H3K4me3 marks in the vicinity of 
promoters. One of the mechanisms involves the interaction between H3K4me3 marks 
and the PHD domain of the basal transcription factor TFIID, suggesting a role of 
H3K4me3 marks in the assembly of the preinitiation complex146,147. These trxG proteins 
each contain a SET domain responsible for methyltransferase enzymatic activity. They 
are enzymatically active only when complexing with accessory proteins148-150. The core 
components of the methyltransferase complexes show evolutional conservation in 
yeasts, drosophila and mammals, although the number of these complexes differs. The 
mammalian counterparts include SET1A/B and MLL1-4. The SET1A/B complexes are 
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major players that contribute to bulk H3K4me3151. Deletion of CFP1, a subunit of 
SET1A/B complexes that target complexes to unmethylated CpG islands and 
H3K4me1/2/3-rich regions, causes global reduction in H3K4me3 levels152. In contrast, 
the MLL1-4 complexes assume a more gene-specific role151. To oppose the promoting 
effects of trxG proteins on gene transcription, PcG proteins form multiprotein 
Polycomb-repressive complex 1 and 2 (PRC1/2) that silence productive gene 
transcription via several mechanisms. PRC1 is capable of compacting chromatin 
independent of its ubiquitin ligase activity, thereby limiting the accessibility of the 
transcriptional machinery to promoters153.  PRC2 catalyzes H3K27 di- or tri-methylation 
through its core subunit EZH1 or EZH2. Other subunits, including SUZ12, EED and 
RbAp46/48, are indispensable for the function of PRC2154,155. EED allosterically activates 
the methyltransferase activity of PRC2 after interacting with PRC2’s own product 
H3K27me3 marks. Deletion of EED leads to global reduction in H3K27me3 levels156. The 
histone chaperones RbAP46 and 48 also contribute to chromatin binding by interacting 
with H3 and H4157. It’s intriguing that H3K4 and H3K27 methyltransferases all require 
accessory proteins to fulfil their enzymatic activity. Involvement of multiple proteins 
may provide additional levels of regulation.  
As noted above, depending on lineage commitment, bivalent domains resolve 
into transcriptionally active or silent domains by removing H3K27me3 or H3K4me3 
marks, respectively. This predicts the existence of tri-methyl histone demethylases158. 
Discovery of JMJD2 in 2006 by several groups, a specific H3K9me2/3 and H3K36me2/3 
demethylase, first refuted the concept that tri-methyl histone marks are generally 
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irreversible due to the high thermodynamic stability of N-CH3 bonds159-161. JMJD2 
belongs the Jumonji protein family, the members of which all contain the conserved 
JmjC domain capable of demethylating histone methyl-groups in a Fe(II) and a-
ketoglutarate-dependent manner. The Jumonji proteins that specifically demethylate 
H3K4me3 include NO66, JARID1A, JARID1B, JARID1C and JARID1D162. In line with their 
function in reducing the transcriptionally active mark H3K4me3, they act as 
transcriptional repressors to silence gene expression. The more recently discovered 
H3K27me3-specific demethylases are UTX and JMJD3108,109,163,164. UTX, but not JMJD3, 
contains tetratricopeptide repeats that mediate protein-protein interaction. UTX and 
JMJD3 erasure of transcriptionally repressive mark H3K27me3 to induce gene 
expression has been extensively reported. These demethylases are essential players in 
resolving bivalency by countering the effects of trG and PcG proteins. An elegant 
example is the robust induction of JMJD3 in LPS-activated macrophages, which 
decreases the H3K27me3 levels on the bivalently marked BMP2 promoter163. These 
results suggested that JMJD3 may contribute to the long-term osteoblast suppression in 
MM. 
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3.2 Results 
 
3.2.1 TNF-a and myeloma cells inhibit Runx2 and Osterix expression in BMSCs by 
resolving the bivalent domains at the TSSs into transcriptionally silent domains 
 
Myeloma cells have been reported to inhibit osteoblast differentiation by direct 
contact with BMSCs or inducing cytokines (DKK1, sclerostin, IL-1b, IL-7, TNF-a et al) in 
bone marrow microenvironment of MM patients. We utilized direct co-culture of the 
5TGM1 murine myeloma cells and the murine early pre-osteoblast cell line MC4 cells as 
one of our in vitro models. Because floating 5TGM1 cells are readily removed from 
adherent MC4 cells by thorough washing with PBS, the expression profile in MC4 cells 
can be selectively examined without concerns of potential contamination. Another in 
vitro model in our study involves 2-day treatment of MC4 cells with 10 ng/ml TNF-a, a 
cytokine that is markedly elevated in sera and marrow aspirates of MM patients. The 
concentration and duration of TNF-a treatment we used was based on previous studies 
that most commonly used this regimen to show inhibition of osteoblast differentiation 
without causing significant cell apoptosis. As expected, MC4 cells treated with 10 ng/ml 
TNF-a or co-cultured with 5TGM1 cells for 2 days showed decreased mRNA levels of 
Runx2 and Osterix (Figure 3-1A). Similar results were also obtained with primary mouse 
BMSCs isolated from tibiae (Figure 3-1B). Consistent with the qPCR results, TNF-a and 
5TGM1 cells decreased protein levels of Runx2 and Osterix in MC4 cells at day 2 and day 
4, respectively (Figure 3-1C).  
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BMSCs from MM patients have been reported to maintain distinct gene profiles 
and persistent defects of osteoblast differentiation. This long-lasting genotype and 
phenotype encouraged us to investigate if epigenetic changes in Runx2 and Osterix 
were involved in the suppression of osteoblast differentiation in MM. As discussed in 
the introduction of this chapter, bivalent domains might be a previously uncharacterized 
mechanism by which the expression of osteoblastogenic genes is regulated. Therefore, 
we characterized the Runx2 and Osterix TSSs by ChIP using antibodies against H3K4me3 
and H3K27me3 in undifferentiated MC4 cells. These studies revealed bivalency at both 
TSSs, which were co-occupied by the transcriptionally active mark, H3K4me3, and the 
transcriptionally repressive mark H3K27me3 (Figure 3-2A and B). As a negative control, 
the intronic region of Runx2 (+33130) was solely occupied by H3K27me3. Using the 
monoclonal cell line MC4 cells instead of isolated mouse BMSCs excluded the possibility 
of “apparent” bivalent domains generated merely by BMSC heterogeneity.  
Resolution of bivalent domains into monovalent domains during lineage 
commitment is not a readily reversible process due to self-enforcement of the same 
type of methyl marks and repellency of different types of marks. Bivalent domains in 
mESCs cannot be restored physiologically during embryogenesis unless ectopic 
overexpression of Yamanaka factors Oct4, Sox2, c-Myc and Klf4 is induced. Therefore, 
we investigated the bivalency at the Runx2 and Osterix TSSs in MC4 cells by ChIP, during 
normal osteoblast differentiation or after the cells were exposed to TNF-a or myeloma 
cells. Compared to the basal levels in untreated MC4 cells at Day 0, H3K4me3 levels 
were increased and H3K27me3 levels were decreased at the Runx2 and Osterix TSSs in 
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MC4 cells that had been cultured in osteogenic medium for 2 days. These epigenetic 
changes paralleled the reduction in Runx2 and Osterix mRNA levels, suggesting the 
ongoing resolution of bivalent domains into transcriptionally active domains. In contrast, 
TNF-a treatment or co-culture of MC4 cells with 5TGM1 cells for 2 days resolved the 
bivalent domains at Runx2 and Osterix TSSs in MC4 cells into transcriptionally silent 
domains. These domains contained decreased H3K4me3 levels and increased 
H3K27me3 levels, resulting in a decreased H3K4me3 to H3K27me3 ratio (Figure 3-3). 
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Figure 3-1: TNF-a and Myeloma Cells Decrease the Expression of Runx2 and Osterix in 
MC4 cells and Mouse BMSCs. 
 
MC4 cells (A) or mouse BMSCs (B) were directly co-cultured with 5TGM1 cells or treated 
with 10 ng/ml TNF-α for 2 days. Relative Runx2 and Osterix mRNA levels in MC4 cells 
were measured by qPCR with the geometric mean of the CT values of b-actin, GAPDH 
and HMBS as the internal control. (C) MC4 cells were treated with 10 ng/ml TNF-α for 2 
days or co-cultured with 5TGM1 cells for 2, 4 and 6 days. Runx2 and osterix protein 
levels in MC4 cells were measured by Western blot with b-actin as the internal control. 
Error bars in each column graph represent SD of three biological replicates. * p < 0.05; 
** p < 0.01; ***p < 0.001 compared with the black bar in individual group. The numbers 
shown in the Western blot indicate normalized densitometry values. 
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Figure 3-2: Bivalent Domains Occupy the TSSs of Runx2 and Osterix in MC4 Cells. 
 
ChIP was performed in undifferentiated MC4 cells using antibodies against H3K4me3 
and H3K27me3. The numbers on x-axis indicate the positions on the Runx2 (A) or 
Osterix (B) promoter with +1 as the first transcribed nucleotide. Error bars in each 
column graph represent SD of three biological replicates. 
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Figure 3-3: Bivalent Domains are Resolved into Transcriptionally Silent Domains at the 
Runx2 and Osterix TSSs in BMSCs by TNF-a. 
 
MC4 cells were cultured in a-MEM medium with or without 10 ng/ml TNF-a for 2 days. 
ChIP was performed using antibodies against H3K4me3 and H3K27me3. The red line 
indicates the basal level of each epigenetic mark in untreated MC4 cells at Day 0. The 
epigenetic changes represent a total of three different sites at the Runx2 TSS and four 
different sites at the Osterix TSS. Error bars in each column graph represent SD of three 
biological replicates. * p < 0.05; ** p < 0.01; ***p < 0.001 compared with the black bar 
in individual group. 
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3.2.2 The H3K27me3-specific demethylase JMJD3 is downregulated in BMSCs from MM 
patients 
 
Resolution of bivalent domains at TSSs into transcriptionally silent domains 
requires simultaneous propagation of H3K27me3 marks and removal of H3K4me3 marks. 
To avoid potential conflicts with our colleagues who are studying H3K4me3 alterations 
in osteoblast differentiation in MM, we mainly focused on the deregulation of 
H3K27me3 levels in BMSCs from MM patients. In addition, EZH2, which catalyzes H3K27 
tri-methylation, has been reported to be overexpressed in a subset of myeloma cells. 
Blocking its enzymatic activity using EZH2-specific inhibitors (E7438, CPI169, GSK126 and 
GSK343) causes global reduction of H3K27me3 levels and relieves the suppression of 
multiple tumor suppressor genes in myeloma cells. In agreement with the change in 
their gene profile, EZH2-specific inhibitor-treated myeloma cells become less 
proliferative and more differentiated compared to untreated cells. Therefore, targeting 
H3K27me3 marks in MM might not only restore the capacity of BMSCs to differentiate 
into mature osteoblasts, but also efficaciously eliminate myeloma cells in combination 
with other chemotherapies. 
To determine if H3K27me3 levels were increased locally at the Runx2 and Osterix 
TSSs or globally in the whole chromatin, we treated MC4 cells or mouse BMSCs with 10 
ng/ml TNF-a or co-cultured them with 5TGM1 cells for 2 days. Western blot analysis of 
whole cell lysates showed that TNF-a treatment and co-culture with 5TGM1 cells 
increased global H3K27me3 levels in both MC4 cells and mouse BMSCs (Figure 3-4A and 
B). This suggests either activation of the H3K27 methyltransferase complex PRC2 or 
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inhibition of the H3K27 demethylases, namely JMJD3 and UTX. Changes in expression 
levels, posttranscriptional modifications (PTMs) or recruiting measures of these histone 
modifiers as well as associated proteins might be the underlying mechanism(s) for the 
increased H3K27me3 marks. Therefore, we first measured by qPCR the expression levels 
of key mediators that control H3K27me3 levels in BMSCs. TNF-a treatment didn’t affect 
the gene expression of PRC2 core components EZH2 or SUZ12, although it slightly 
decreased EED gene expression (Figure 3-5A). We found that JMJD3 was the 
predominant H3K27me2/3 demethylase in both MC4 cells and mouse BMSCs since its 
gene expression was 40 to 80 fold greater than that of UTX (Figure 3-5B). Both TNF-a 
treatment and co-culture with 5TGM1 cells decreased JMJD3 mRNA and protein levels 
in MC4 cells (Figures 3-5C). Similar changes were also found in mouse BMSCs (Figure 3-
5D).  
To correlate our in vitro findings with what actually occurs in MMBD, we isolated 
human BMSCs from marrow aspirates of age-matched healthy donors and MM patients. 
P0 BMSCs were obtained by culturing BM mononuclear cells in IMDM medium for 3 
weeks. Only P2 and P3 BMSCs were used in the following experiments. Importantly, 
Western blot analysis showed that BMSCs from MM patients had markedly decreased 
JMJD3 protein levels compared to healthy donor BMSCs, even in the absence of 
myeloma cells for more than one month (Figure 3-6A). Densitometry analysis of 
Western blots by ImageJ further demonstrated the downregulation of JMJD3 in BMSCs 
from MM patients (Figure 3-6B). These data collectively suggest the potential 
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contribution of JMJD3 to the pathogenesis of lytic bone lesions in MM. Identifying 
negative regulators of JMJD3 may open novel therapeutic options to treat MMBD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
 
 
Figure 3-4: TNF-a and Myeloma Cells Increase Global H3K27me3 Levels in Stromal 
Cells. 
 
MC4 cells (A) or mouse BMSCs (B) were treated with 10 ng/ml TNF-a or co-cultured 
with 5TGM1 cells for 2 days. Global H3K27me3 protein levels were measured by 
Western blot with b-actin as the internal control. The numbers shown in the Western 
blot indicate normalized densitometry values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vehicle +TNF-α +5TGM1
H3K27me3
β-actin
1.73±0.25 1.93±0.381
A
H3K27me3
β-actin
Vehicle TNF-α
1.36±0.061
B
MC4 BMSC
62 
 
 
 
Figure 3-5: TNF-a and Myeloma Cells Decrease the Expression of the H3K27me2/3 
Demethylase JMJD3 in Stromal Cells. 
 
(A) MC4 cells were treated with 10 ng/ml TNF-α for 2 days. Relative mRNA levels of Ezh2, 
Eed, and Suz12 in MC4 cells were measured by qPCR with the geometric mean of the CT 
values of b-actin, GAPDH and HMBS as the internal control. (B) Relative mRNA levels of 
JMJD3 and UTX in untreated MC4 cells and mouse BMSCs were measured by qPCR with 
the geometric mean of the CT values of b-actin, GAPDH and HMBS as the internal 
control. MC4 cells (C) or mouse BMSCs (D) were treated with 10 ng/ml TNF-a or co-
cultured with 5TGM1 cells for 2 days. JMJD3 mRNA level was measured using qPCR with 
the geometric mean of the CT values of b-actin, GAPDH and HMBS as the internal 
control. JMJD3 protein levels were measured by western with b-actin as the internal 
control. Error bars in each column graph represent SD of three biological replicates. * p 
< 0.05; ** p < 0.01; ***p < 0.001 compared with the black bar in individual group. The 
numbers shown in the Western blot indicate normalized densitometry values. 
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Figure 3-6: JMJD3 Protein Levels were Decreased in BMSCs Isolated from MM Patients. 
 
(A) Human BMSCs were isolated from bone marrow of healthy donors and myeloma 
patients, and cultured until passage 3. JMJD3 protein levels in human BMSCs were 
measured using Western blot with b-actin as the internal control. (B) Densitometry 
analysis of JMJD3 protein levels in BMSCs isolated from healthy donors and MM 
patients was performed. Error bars in each column graph represent SD of three 
biological replicates. * p < 0.05; ** p < 0.01; ***p < 0.001 compared with the black bar 
in individual group. The numbers shown in the Western blot indicate normalized 
densitometry values. 
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3.2.3 JMJD3 contributes to normal osteoblast differentiation 
 
We then assessed if JMJD3 regulated Runx2 and Osterix expression in MC4 cells. 
By delivering two different sets of ON-TARGETplus siRNAs that targeted mouse JMJD3 
ORF regions, JMJD3 was knocked down by approximately 50% in MC4 cells (Figure 3-7A). 
The JMJD3 knockdown efficiency was optimized by adjusting the concentration of 
siRNAs used in transfection to mimic the extent of JMJD3 downregulation in MC4 cells 
treated with TNF-a or co-cultured with 5TGM1 cells. We used ONTARGETplus siRNAs 
because of their few off-target effects. Knockdown of JMJD3 in MC4 cells decreased the 
mRNA and protein levels of Runx2 and Osterix compared to MC4 cells transfected with 
scrambled siRNA (Figure 3-7B). Further supporting the role of JMJD3 in osteoblast 
differentiation, we cloned the full-length mouse JMJD3 gene into the iCumate-pLenti-
Cloning-SV40-GFP lentiviral vector. JMJD3 expression was driven by a hybrid CMV 
promoter. MC4 cells stably infected with the JMJD3-overexpressing vector (MC4/JMJD3 
cells) had a 30% increase in JMJD3 expression compared to cells infected with an empty 
vector (MC4/EV cells) (Figure 3-8A). Consistent with JMJD3 knockdown data, ectopic 
overexpression of JMJD3 in MC4/JMJD3 cells increased Runx2 and Osterix mRNA and 
protein levels (Figure 3-8B). To determine if JMJD3 overexpression in osteoblast 
precursors ultimately affects mineralization activity of mature osteoblasts, we cultured 
both MC4/EV and MC4/JMJD3 cells in osteogenic medium for 14 and 21 days. 
Mineralization activity was semi-quantitatively measured by Alizarin Red S, which forms 
a bright red stain after chelating calcium. As shown in Figure 3-9C, Alizarin Red S staining 
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showed enhanced mineralization of MC4/JMJD3 cells compared to MC4/EV cells after 
they were cultured in osteogenic medium for 14 and 21 days.  
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Figure 3-7: Knockdown of JMJD3 in MC4 Cells Decrease the Expression of Runx2, 
Osterix and ALP. 
 
MC4 cells were transfected with scrambled siRNA or two different sets of JMJD3 siRNA. 
The mRNA and protein levels of JMJD3 (A), Runx2, Osterix and ALP (B) were measured 
48 hours later by qPCR and Western blot, respectively; Error bars in each column graph 
represent SD of three biological replicates. * p < 0.05; ** p < 0.01; ***p < 0.001 
compared with the black bar in individual group. The numbers shown in the Western 
blot indicate normalized densitometry values. 
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Figure 3-8: Ectopic Overexpression of JMJD3 in MC4 Cells Contributes to Osteoblast 
Differentiation and Mineralization. 
 
MC4 cells were stably infected with an empty vector (EV) or JMJD3-overexpressing 
lentivirus (JM). The mRNA and protein levels of JMJD3 (A), Runx2 and Osterix (B) were 
measured by qPCR and Western blot, respectively. (C) MC4 cells stably infected with EV 
or JM were cultured in osteogenic medium for 14 and 21 days. Alizarin Red S staining 
was performed to assess mineralization activity. Error bars in each column graph 
represent SD of three biological replicates. * p < 0.05; ** p < 0.01; ***p < 0.001 
compared with the black bar in individual group. The numbers shown in the Western 
blot indicate normalized densitometry values. 
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3.3 Discussion 
 
BMSCs from myeloma patients differ in many aspects compared with those from 
healthy donors, including spontaneous or myeloma-induced cytokine production56,57, 
support of MM cell-mediated drug resistance58,59, enhancement of MM proliferation60, 
and impaired osteoblast differentiation potential52-55. Dysregulated gene and microRNA 
profiles in BMSCs from MM patients have been demonstrated and provide valuable 
insight into how they possibly contribute to distinct phenotypes of BMSCs in MM. 
However, how healthy BMSCs gradually become malfunctioning BMSCs in MM patients 
and how these defects are maintained in the absence of MM cells are still unclear.  
We found co-occupancy of H3K4me3 and H3K27me3 marks, known as bivalent 
domains, at the Runx2 and Osterix TSSs in BMSCs, and that TNF-a and MM cells 
resolved these bivalent domains into transcriptionally silent domains. This observation is 
consistent with previous studies showing that histone methylation is constantly subject 
to the regulation of methyltransferases and demethylases, and that the equilibrium 
between H3K4me3 and H3K27me3 levels on bivalent domains is kept delicately 
balanced unless it’s severely disturbed. Bivalent domains developmentally resolve into 
either transcriptionally active domains featured by predominance of H3K4me3 marks 
over H3K27me3 marks, or transcriptionally silent domains featured by predominance of 
H3K27me3 marks over H3K4me3 marks96. Each epigenetic state is stably maintained in a 
noise-resistant manner by self-enforcement, resulting from the ability of methylated 
histones to propagate the same type of methylation as well as remove the competing 
type of methylation on neighboring histones. In the scenario of transcriptionally silent 
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domains, H3K27me3 marks help recruit more PRC2 complexes that mediate H3K27 tri-
methylation by binding its component EED156. Moreover, they destabilize the interaction 
between H3 and H3K4 methyltransferase complexes105. This demonstrates a positive 
feedback loop that reinforces its epigenetic memory in the absence of the initial 
developmental cue. Therefore, our results provide a mechanism by which suppression 
of osteoblast differentiation persists in MM patients after complete remission. Of note, 
we were unable to show that TNF-a increased H3K27me3 levels on the Runx2 promoter, 
which may contradict with the findings of two other studies that reported that silencing 
JMJD3 via knockdown or knockout techniques accumulates H3K27me3 marks on the 
Runx2 promoter165,166. One possible explanation is that TNF-a signaling in addition to 
decreasing JMJD3 expression may also affect other aspects of JMJD3, such as PTMs of 
JMJD3 following activation of a variety of kinases by TNF-a and its recruitment by 
accessary proteins to the Runx2 promoter. 
We found persistently decreased expression of JMJD3 in BMSCs from myeloma 
patients compared to BMSCs from healthy donors, even after the BMSCs were cultured 
in the absence of myeloma cells for more than one month. These data suggest a 
potential role for loss of JMJD3 in the inhibition of osteoblast differentiation in MM. 
JMJD3 has been found to play essential roles in cell differentiation167-169, 
inflammation163,170, wound healing171,172 and tumorigenesis173-175. Importantly, JMJD3 
plays an important role in bone formation since it not only contributes to 
intramembranous and endochondral ossification, but also helps maintain bone 
homeostasis. Silencing JMJD3 suppresses osteoblast differentiation in vitro and in 
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vivo165,166. However, the role of JMJD3 in pathological bone disease has not been 
investigated. Our results suggest that loss of JMJD3 contributed to the pathogenesis and 
maintenance of MMBD. However, our study was limited to clarifying the demethylase-
dependent function of JMJD3 on Runx2 and Osterix expression in BMSCs. The other 
genes affected by JMJD3 in BMSCs and the demethylase-independent functions of 
JMJD3 were not investigated and are beyond the scope of this study. We cannot exclude 
that decreased production of other factors regulated by JMJD3 may also participate in 
MMBD. The endogenous levels of osteogenic cytokine BMP2/4 in BMSCs have been 
reported to decrease in cells with JMJD3 knockdown176. Bcl-2, an anti-apoptotic protein, 
is also downregulated in JMJD3-knockdown MC3T3-E1 cells, inducing intrinsic 
mitochondrial apoptosis of osteoblasts177. In addition, JMJD3 interacts with other 
proteins independent of its demethylase activity to regulate their activity. Chen et al. 
reported that JMJD3 recruits the transcription elongation factors SPT6/16 to support 
productive transcriptional elongation110. Thus, characterizing if these other known 
effects of JMJD3 contribute to MMBD are fruitful areas for further investigation. 
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CHAPTER 4 
TNF-a MEDIATED REGULATION OF JMJD3 GENE EXPRESSION 
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4.1 Introduction 
 
Adaptation to the surrounding environment requires the ability of cells to 
convert ephemeral stimuli into persistent phenotypic changes. One excellent example is 
“ischemic preconditioning” of cardiomyocytes in patients who are suffering from 
coronary heart diseases. Recurrent ischemic episodes/angina switches cardiomyocytes 
to a long-lasting low metabolic status and protects patients against serious 
complications if myocardial infarction follows178. One underlying mechanism responsible 
for persistent phenotypic changes involves the PTMs on histone tails.  The density and 
variety of PTMs on histone tails function as a platform that incorporates multiple on and 
off signals received by cells and convert them into a few directed outputs: increased or 
decreased gene expression. This feature of histone modifications is comparable to a 
multiple-inputs-single-output system125. Characterizing the signaling pathways that relay 
extracellular stimuli to histone PTMs in nucleus is imperative to understand how cells 
maintain their phenotypes after the initial stimuli are long gone, and may provide a way 
to reverse the unfavorable traits cells acquire in a pathological setting.  
Emerging evidence has shown that varying levels of metabolites are able to 
reshape the chromatin landscape by directly regulating the enzymatic activity of histone 
modifiers. For example, accumulating b-hydroxybutarate during starvation inhibits 
HDAC activity and increases global histone acetylation179. a-ketoglutarate, an 
intermediate metabolite involved in Krebs Cycle and protein transamination, enhances 
the histone demethylating activity of Jumonji proteins180,181. Further, several signaling 
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cascades have been reported to catalyze PTMs of histone modifiers, modulate their 
expression levels or recruit them to specific loci by activated transcription factors. A 
well-studied signaling pathway capable of modifying histone tails is PI3K-AKT. Activation 
of PI3K-AKT in response to growth factors, hormones and extracellular matrix 
phosphorylates the histone modifiers that contain the sequence within AKT consensus 
motifs, including the H3K27 methyltransferase EZH2182, the H2AK119 ubiquitin ligase 
BMI1183, the histone acetyltransferase p300184, the H3K9 demethylase KDM4B and the 
H3K4 methyltransferase SET1A (identified in large proteomic studies). Phosphorylation 
of these histone modifiers significantly changes their enzymatic activity or protein 
stability. Other signaling pathways that actively regulate histone modifications include 
MAPKs185,186, NF-kB187, PKA188 and CDK1/2189-193.  During osteoblast differentiation, 
sustained CDK1 activation in human BMSCs phosphorylates EZH2 at Thr 487, leading to 
compromised EZH2 methyltransferase activity, decreased global H3K27me3 levels and 
an accessible chromatin landscape on osteoblast-specific genes193.  
The H3K27me2/3 demethylase JMJD3 is presumably regulated by PTMs, 
upstream transcription factors and gene-specific recruitment, similar as other histone 
modifiers. In support of this notion, human JMJD3 possibly has 20 phosphorylation sites, 
2 ubiquitination sites, 2 acetylation sites and 1 sumoylation site over the entire 1643 
amino acid sequence based on the bioinformatics prediction of iPTMnet 
(http://research.bioinformatics.udel.edu/iptmnet/). Consistent with iPTMnet, the 
database PhosphoSitePlus (https://www.phosphosite.org/) shows 22 phosphorylation 
sites on human JMJD3 based on low- and high- throughput mass spectrometry (MS) 
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data collected over 16 years. However, the biological effects of individual PTM sites on 
JMJD3 function haven’t been investigated experimentally and should be a promising 
direction for future research. Besides PTMs, the gene expression of JMJD3 is under the 
regulation of multiple signaling pathways. Yang et al. have reported that JMJD3 is 
markedly induced in the pre-osteoblast MC3T3-E1 cells treated with BMP-2 and that 
silencing of the downstream mediators Smad1/5 by siRNA inhibits JMJD3 induction165. In 
an independent study by Fei at al., ChIP analyses using anti-SMAD1/5 and anti-SMAD4 
antibodies have shown that SMAD1/4/5 occupy the mouse JMJD3 promoter in 
undifferentiated R1 ES cells194. These studies collectively suggest the involvement of 
BMP2-SMADs signaling in activating JMJD3 gene transcription. Interestingly, SMADs 
directly interact with JMJD3 and recruit JMJD3 to their target genes195,196. Other 
recognized signaling pathways capable of regulating JMJD3 expression include NF-
kB163,197, STATs170, and vitamin D173,198. In last chapter, we found decreased JMJD3 
expression in BMSCs treated with TNF-a or co-cultured with myeloma cells for 2 days. In 
line with the in vitro findings, BMSCs isolated from MM patients expressed significantly 
lower levels of JMJD3 compared to BMSCs isolated from age-matched healthy donors. 
The molecular mechanism(s) responsible for the downregulation of JMJD3 in stromal 
cells in MM, however, remains to be determined.  
We utilized MC4 cells treated with TNF-a as our in vitro model to pinpoint the 
signaling pathway(s) that inhibits JMJD3 expression. The activation of TNF-a signaling 
starts from binding of homotrimeric TNF-a to its cognate receptors: TNF receptor type 1 
(TNF-R1) and TNF receptor type 2 (TNF-R2). This interaction is followed by 
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reorganization of pre-assembled TNF receptors, dissociation of silencer of death domain 
(SODD) to expose the death domain (DD) of TNF receptors, and subsequent recruitment 
of death domain-containing adaptor protein TRADD. Other adaptor proteins, kinases, 
ubiquitin ligases and proteases then join to mediate the pleiotropic biological effects of 
TNF-a signaling. The stereotyped mediators that TNF-a activates include NF-kB, ERK, 
JNK, p38 and caspases40. PI3K/AKT199 and STATs200 have also been reported to be 
activated by TNF-a in certain cell types. Gilbert et al. reported that pretreatment of 
BMSCs and MC3T3-E1 cells with three different caspase inhibitors fails to prevent the 
inhibitory effects of TNF-a on osteoblast differentiation, suggesting the unimportant 
role of TNF-a-induced apoptosis in regulating osteoblast differentiation201. This finding 
encouraged us to focus on the pathways other than apoptosis.  Despite of the extensive 
research for more than 40 years, the signaling map of TNF-a is far from complete. The 
possible existence of unidentified mediators of TNF-a signaling might be the caveat of 
our study.  
As discussed in the Chapter 1.3, we showed that Gfi1 expression in BMSCs is 
induced by MM cells to mediate long-term suppression of osteoblast differentiation64. 
Gfi1 recruits the histone modifiers HDAC1 and EZH2 to the Runx2 promoter, which 
cause H3K9ac deacetylation and H3K27 tri-methylation, respectively.  These epigenetic 
changes inhibit Runx2 productive transcription and persist after removal of myeloma 
cells. Ectopic overexpression of Gfi1 in stromal cells is sufficient to maintain Runx2 
suppression in osteogenic conditions78. Considering our recent finding that decreased 
JMJD3 expression in BMSCs similarly contributes to the repressive remodeling of 
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epigenetic landscape on the Runx2 promoter, it’s intriguing to investigate the possible 
interaction between Gfi1 and JMJD3. Our preliminary studies identified multiple Gfi1 
binding sites existing on the mouse and human JMJD3 promoter based on the 
bioinformatics prediction of JASPAR core database (http://jaspar.genereg.net/). It’s 
currently unknowing if Gfi1 could inhibit JMJD3 transcription by bringing repressive 
histone marks to the JMJD3 promoter as it does to the Runx2 promoter. If so, this may 
explain the sustained suppression of JMJD3 expression in BMSCs isolated from MM 
patients compared to BMSCs from healthy donors, even after MM cells were removed 
more than one month before.   
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4.2 Results 
 
4.2.1 NF-kB pathway activation is responsible for the downregulation of JMJD3 induced 
by prolonged TNF-a Treatment 
 
TNF-a activates several signaling pathways, including NF-kB, JNK, p38, ERK1/2 
and apoptosis. We investigated the detailed molecular mechanism(s) that regulated 
JMJD3 expression to identify targetable proteins to mitigate the effects of decreased 
JMJD3 in MMBD, since no specific JMJD3 agonist has been developed. MC4 cells were 
treated with 10 ng/ml TNF-a for 0.5, 1, 2, 6, 24 and 30 hours. qPCR data showed that 
JMJD3 gene expression was initially induced in MC4 cells treated with TNF-a but 
became persistently lower after 6 hours compared to MC4 cells treated with vehicle 
(Figure 4-1). This finding suggests that prolonged TNF-a treatment, which models the 
chronic elevation of TNF-a levels in bone marrow microenvironment in MM, is needed 
to decrease JMJD3 gene expression. To determine the signaling pathway(s) responsible 
for the downregulation of JMJD3 by TNF-a, MC4 cells were pretreated for 2 hours with 
70 µM NF-kB inhibitor quinazoline (QNZ), 10 µM JNK inhibitor SP600125, 10 µM p38 
inhibitor SB203580 or 20 µM MEK1 inhibitor PD98059, followed by TNF-a treatment for 
24 hours. This experimental regimen was utilized because TNF-a consistently decreased 
JMJD3 expression in MC4 cells after 24-hour treatment and the cytotoxicity of each 
inhibitor was minimized with shorter exposure time. The optimal concentration of each 
inhibitor needed to block individual signaling pathway in MC4 cells was also determined 
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experimentally (Figure 4-2). qPCR data showed that none of the MAPK inhibitors 
reversed the inhibition of JMJD3 expression in MC4 cells treated with TNF-a (Figure 4-
3A). In contrast, the NF-kB inhibitor QNZ partially rescued the inhibition of JMJD3 
expression (Figure 4-3B). QNZ is a potent inhibitor of NF-kB transcriptional activation 
permeable to cells. QNZ was selected over BAY 11-7082 and Bortezomib in our study 
due to its minimal cytotoxicity and high specificity (data not shown).  
Chauhan et al. has reported that adhesion of the MM cell line IM-9 with the 
BMSC line LP101 induces IL-6 expression in LP101 cells. A single base pair deletion of the 
NF-kB binding site on the IL-6 promoter blocks MM-mediated IL-6 induction. This finding 
indicates the activation of NF-kB signaling in stromal cells directly co-cultured with 
myeloma cells in their system, although phosphorylation and nuclear translocation of 
p65, the hallmark of NF-kB activation, was not shown. We investigated if the myeloma 
cell line 5TGM1 could activate NF-kB signaling in MC4 cells the same way as TNF-a 
treatment to inhibit JMJD3 gene expression. MC4 cells were treated with 10 ng/ml TNF-
a, the conditioned medium from 5TGM1 cells, or directly co-cultured with 5TGM1 cells 
for 15 and 30 minutes. IkB degradation was measured by Western blot as the readout of 
NF-kB activation. Western blot showed that TNF-a rapidly induced IkB degradation in 
MC4 cells. Conversely, neither the conditioned medium from 5TGM1 cells nor the direct 
contact with 5TGM1 cells degraded IkB in MC4 cells at 15 and 30 minutes, suggesting 
the lack of NF-kB activation in both conditions (Figure 4-3C). These results imply either a 
completely different mechanism by which 5TGM1 cells inhibit JMJD3 gene expression in 
MC4 cells through direct cell-cell interaction or inadequate levels of TNF-a expressed by 
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MM cells to show similar results. However, investigating a novel mechanism responsible 
for these results is beyond the scope of my dissertation. 
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Figure 4-1: TNF-a Regulates JMJD3 Gene Expression in a Time-dependent Manner. 
 
MC4 cells were treated with 10 ng/ml TNF-a for 0.5, 1, 2, 6, 24 and 30 hours. JMJD3 
mRNA level was measured using qPCR with the geometric mean of the CT values of b-
actin, GAPDH and HMBS as the internal control. Error bars in each column graph 
represent SD of three biological replicates. * p < 0.05; ** p < 0.01; ***p < 0.001 
compared with the black bar in individual group. 
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Figure 4-2: Determining the Optimal Concentration of Small Molecule Inhibitors to 
Block the Signaling Pathways Activated by TNF-a. 
 
(A) MC4 cells were pretreated with DMSO or 20 µM PD98059 for 2 hours, followed by 
10 ng/ml TNF-a treatment for 15 minutes. Phospho-Erk1/2 protein level was measured 
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by western bot with total Erk1/2 as the internal control; (B) p38 activation has been 
reported to mediate IL-6 induction by TNF-a treatment. MC4 cells were pretreated with 
DMSO or 10 µM SB203580 for 2 hours, followed by 10 ng/ml TNF-a treatment for 6 
hours. IL-6 mRNA level was measured using qPCR with the geometric mean of the CT 
values of b-actin, GAPDH and HMBS as the internal control; (C) MC4 cells were 
pretreated with DMSO or 10 µM SP600125 for 2 hours, followed by 2 or 10 ng/ml TNF-a 
treatment for 15 minutes. Phospho-c-Jun protein level was measured by western bot 
with total c-Jun as the internal control; (D) MC4 cells were pretreated with DMSO, 20 or 
70 µM QNZ for 2 hours, followed by 10 ng/ml TNF-a treatment for 2 hours. The mRNA 
levels of TNF-a and A20, which have been shown to be induced by TNF-a treatment, 
were measured using qPCR with the geometric mean of the CT values of b-actin, GAPDH 
and HMBS as the internal control; The red dotted line in each column graph represents 
the basal level of the measured gene before TNF-a treatment. Error bars in each column 
graph represent SD of three biological replicates. * p < 0.05; ** p < 0.01; ***p < 0.001 
compared with the black bar in individual group. The numbers shown in the Western 
blot indicate normalized densitometry values. 
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Figure 4-3: The Activation of NF-kB Signaling by TNF-a Mediates the Inhibition of 
JMJD3 Gene Expression. 
 
MC4 cells were pretreated with equal volume of DMSO, 20 µM MEK1 inhibitor PD98059, 
10 µM p38 inhibitor SB203580, 10 µM JNK inhibitor SP600125 (A), or 20 and 70 µM NF-
kB inhibitor QNZ (B) for 2 hours. MC4 cells were then treated with 10 ng/ml TNF-a for 
24 hours. JMJD3 mRNA level was measured using qPCR with the geometric mean of the 
CT values of b-actin, GAPDH and HMBS as the internal control; (C) The conditioned 
medium (CM) was collected by culturing 106/ml 5TGM1 cells for 2 days. MC4 cells were 
treated with 10 ng/ml TNF-a, CM or co-cultured with 5TGM1 cells for 15 and 30 minutes. 
IkB-a protein level was measured by western bot with b-actin as the internal control. 
Error bars in each column graph represent SD of three biological replicates. * p < 0.05; 
** p < 0.01; ***p < 0.001 compared with the black bar in individual group. The numbers 
shown in the Western blot indicate normalized densitometry values. 
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4.2.2 Induction of Gfi1 by TNF-a and MM cells is not responsible for the downregulation 
of JMJD3 
 
We reported that Gfi1 induced by MM cells and TNF-a treatment represses 
Runx2 expression and osteoblast differentiation in BMSCs from MM patients. As a 
transcriptional repressor, Gfi1 binds to its cognate consensus DNA sequence AA(T/G)C 
and recruits histone modifiers, including LSD-1/CoRest, HDAC1/2/3, G9a and EZH2, to 
reversibly and irreversibly impair target gene transcription. The inverse correlation of 
Gfi1 and JMJD3 expression levels and the shared functionality in regulating osteoblast 
differentiation encouraged us to investigate their possible interactions.  We found that 
multiple Gfi1 binding sites are present on the human (Table 4-1A) and mouse (Table 4-
1B) JMJD3 promoters based on the bioinformatics analysis using the JASPAR core 
database (http://jaspar.genereg.net/). It’s reasonable to infer that targeting of Gfi1 to 
the JMJD3 promoter should accumulate transcriptionally repressive histone marks and 
block JMJD3 gene transcription. To validate if JMJD3 expression was regulated by Gfi1 in 
BMSCs, we transiently overexpressed flag-tagged Gfi1 in MC4 cells (Figure 4-4A). MC4 
cells transfected with a Gfi1-overexpressing plasmid had a similar expression level of 
JMJD3 compared to MC4 cells transfected with an empty vector (Figure 4-4B). This 
finding argues against the transcriptional regulation of JMJD3 by Gfi1 in MC4 cells. 
Further supporting this, similar findings were also obtained in 293FT cells (Figure 4-5). 
These results collectively demonstrate that MM cells employ at least two independent 
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mechanisms to induce long-term suppression of osteoblast differentiation, persistent 
upregulation of Gfi1 and downregulation of JMJD3. 
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A. Predicted Gfi1 binding sites on the human JMJD3 promoter 
Predicted Site Sequence Strand Start End Relative Score 
CCAATCTCCA -1 -2000 -1991 0.865 
CAAATCTGCC -1 -1930 -1921 0.873 
TTAATCCCTC -1 -1381 -1372 0.812 
TAAAGCTCTG 1 -1374 -1365 0.827 
CTAATCTCTA -1 -877 -868 0.823 
CCAATCTAAT -1 -872 -863 0.827 
TTAATCATAG -1 -828 -819 0.837 
 
B. Predicted Gfi1 binding sites on the mouse JMJD3 promoter 
Predicted Site Sequence Strand Start End Relative Score 
CAAATCCCCA -1 -1877 -1868 0.865 
TAAATCATTT -1 -1736 -1727 0.866 
AGAATCTGTG 1 -1483 -1474 0.845 
GAAATAACAC 1 -935 -926 0.807 
TAAGTCTCTG 1 -856 -847 0.806 
GAAAACACTG 1 -768 -759 0.842 
CCAGTCACAG 1 -512 -503 0.826 
CGAATCTCCC 1 -116 -107 0.857 
 
Table 4-1: Prediction of Gfi1 Binding Sites on the JMJD3 Promoter Using JASPAR Core 
Database. 
 
2000 bp DNA sequences upstream of the TSSs of both the mouse and human JMJD3 
genes were obtained using Ensembl Genomes (http://ensemblgenomes.org/) and 
regarded as their promoter regions. These sequences were subsequently analyzed using 
JASPAR core database to predict Gfi1 binding sites based on Gfi1 DNA-binding matrix 
profile. In the column “Strand”, “1” indicates leading DNA strand and “-1” indicates 
complementary DNA strand. The column “Start” and “End” marks the position of the 
potential Gfi1 binding sites relative to the first transcribed nucleotide of JMJD3.  
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Figure 4-4: Gfi1 does not Regulate JMJD3 Gene Expression in MC4 cells. 
 
MC4 cells were transiently transfected with empty pcDNA3.1 vector (EV) or flag-tagged 
Gfi1-overexpressing pcDNA3.1 (Gfi1 o/e) for 2 days. (A) Gfi1 mRNA level was measured 
using qPCR with the geometric mean of the CT values of b-actin, GAPDH and HMBS as 
the internal control. Gfi1 protein levels were measured by western with b-actin as the 
internal control; (B) JMJD3 mRNA level was measured using qPCR with the geometric 
mean of the CT values of b-actin, GAPDH and HMBS as the internal control. Error bars in 
each column graph represent SD of three biological replicates. * p < 0.05; ** p < 0.01; 
***p < 0.001 compared with the black bar in individual group. 
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Figure 4-5: Gfi1 does not Regulate JMJD3 Gene Expression in 293FT cells. 
 
293FT cells were transiently transfected with empty pcDNA3.1 vector (EV) or flag-tagged 
Gfi1-overexpressing pcDNA3.1 (Gfi1 o/e) for 2 days. (A) Gfi1 mRNA level was measured 
using qPCR with the geometric mean of the CT values of b-actin, GAPDH and HMBS as 
the internal control. Gfi1 protein levels were measured by western with b-actin as the 
internal control; (B) JMJD3 mRNA level was measured using qPCR with the geometric 
mean of the CT values of b-actin, GAPDH and HMBS as the internal control. Error bars in 
each column graph represent SD of three biological replicates. * p < 0.05; ** p < 0.01; 
***p < 0.001 compared with the black bar in individual group. 
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4.3 Discussion 
 
We have shown that suppressed JMJD3 expression in BMSCs impaired osteoblast 
differentiation by resolving the bivalent domains on the Runx2 and Osterix promoters to 
transcriptionally silent domains. This molecular mechanism, together with elevated Gfi1 
expression in BMSCs, contributes to the protracted lytic bone lesions in MM patients. 
One would assume that activating JMJD3 enzymatic activity or restoring its expression 
level in BMSCs could mitigate MMBD. However, no specific JMJD3 agonist is currently 
available for both clinical and research use. Further, it is unlikely one will be developed 
in the near future due to the conserved amino acid sequences shared by a group of 27 
proteins, 15 of which possess demethylase activity202.  
By determining the upstream signaling that regulates JMJD3 transcription, we 
suggest alternative ways to target JMJD3 and possibly reverse MMBD in patients. One 
solution is to use a JMJD3 physiological agonist—the H3K27 methyltransferase EZH2 
inhibitor—to counteract the accumulation of repressive H3K27me3 marks on genes 
orchestrating osteoblast differentiation. In agreement with the feasibility of this notion, 
Adamik et al. reported that blocking EZH2 enzymatic activity with the small molecule 
inhibitor GSK126 reverses MM-induced suppression of osteoblast differentiation78. In 
addition, myeloma cells isolated from MM patients and MM cell lines express higher 
levels of EZH2 compared to their control counterparts203,204. Inhibition of EZH2 using 
small molecules arrests tumor growth and sensitizes tumor cells to routine MM 
chemotherapy204,205. The other solution involves targeting the NF-kB signaling pathway 
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that we have shown regulated JMJD3 transcription. Inhibiting NF- kB activation in MM 
patients could potentially mitigate MMBD and offers several advantages. First, NF- kB 
serves as the signaling hub activated by a variety of inflammatory cytokines elevated in 
the bone marrow microenvironment of MM patients, including TNF-a, IL-1b21,206, B-cell 
activating factor (BAFF)207,208, a proliferation-inducing ligand (APRIL)207 and 
lymphotoxin209. Antagonizing NF- kB should be more effective than targeting an 
individual cytokine. Second, JMJD3 has been reported to exert its biological functions 
without demethylating associated proteins. For example, the promoting effects of 
JMJD3 on target gene expression not only depends on its activity to remodel 
surrounding epigenetic landscape, but also recruits the transcription elongation factors 
SPT6/16 to ensure productive transcription110. Therefore, restoring JMJD3 expression in 
BMSCs with NF- kB inhibitors alleviates MM-induced suppression of osteoblast 
differentiation both dependent and independent of its demethylase activity.  
It’s worth noting that previous studies have shown transient upregulation of 
JMJD3 transcription by activating NF- kB in macrophages163 and vascular endothelial 
cells210. They are consistent with our results in MC4 cells exposed to TNF-a treatment 
within 6 hours. Interestingly, after 6 hours JMJD3 expression decreased and remained 
suppressed thereafter. This result demonstrates the time-dependent regulation of 
JMJD3 by NF-kB signaling and supports the contribution of chronic inflammation to 
bone lesions in MM patients. The detailed mechanisms of how NF-kB activation inhibits 
JMJD3 expression still remains to be determined in future studies. Two studies may 
shed light on this research question.  Levy et al. have reported that mono-methylation 
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of activated p65 by SETD6 in nucleus creates a docking site for the H3K9 
methyltransferase G9a-like protein (GLP) and subsequently represses NF-kB target gene 
expression by inducing H3K9 methylation, which is the epigenetic mark of 
heterochromatin187. This study could explain both the temporal changes of JMJD3 
expression following NF-kB activation and the sustained suppression of JMJD3 
expression in BMSCs isolated from MM patients. Another study by Yamazaki et al. found 
that activated p65 complexes with SMAD1/4 and interferes with their DNA binding 
activity211. As discussed in Chapter 4.1, SMAD1/4 transcriptionally activate JMJD3. 
Therefore, disruption of SMADs by NF-kB activation should inhibit JMJD3 gene 
expression. 
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CHAPTER 5 
JMJD3 OVEREXPRESSION IN MC4 CELLS PARTIALLY OVERCOMES THE SUPPRESSION OF 
OSTEOBLAST DIFFERENTIATION BY TNF-a 
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5.1 Introduction 
 
Multiple molecular mechanisms have been reported to be responsible for TNF-
a-induced suppression of osteoblast differentiation. Gilbert et al has shown that TNF-a 
inhibits the expression of insulin-like growth factor I (IGF-1), a growth factor that 
stimulates osteoblast differentiation via activating mammalian target of rapamycin 
(mTOR) pathway212. They have also found that TNF-a shortens the half-life of Runx2 
mRNA from 1.8 h to 0.9 h213. Consistent with the inhibitory effects of TNF-a on Runx2 
expression, Kaneki et al has reported that TNF-a induces the expression of Runx2 E3 
ubiquitin ligases, Smurf1 and Smurf2, in osteoblast precursor cell lines, resulting in 
proteasome-mediated degradation of endogenous Runx2 protein.  Treating cells with 
the proteasomal inhibitor MG132 or transfecting cells with Smurf1/2 siRNAs blocks 
Runx2 degradation214. Lu et al has reported that TNF-a markedly increases the gene 
expression of paired related homeobox protein (Prx1) that accumulates on the 
promoter regions of Runx2 and Osterix, and impairs their transcription215. In addition to 
inducing negative regulators of osteoblast differentiation, TNF-a disrupts the osteogenic 
BMP-2 signaling by preventing phosphorylation of SMADs216, interfering with the DNA 
binding of SMADs217, and increasing the transcriptional repressor Msx2218. Other 
mechanisms have been thoroughly discussed in the review by Osta et al.  
We have shown that prolonged TNF-a treatment decreased JMJD3 gene 
expression in BMSCs. Further, JMJD3 knockdown using siRNA alone was sufficient to 
inhibit osteoblast differentiation. Our findings collectively suggest a novel mechanism by 
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which TNF-a negatively regulates osteoblast differentiation. However, little is known 
about how much JMJD3 downregulation in BMSCs contributes to the suppression of 
osteoblast differentiation in the inflammatory microenvironment of patients with 
MMBD. Currently over ten molecular mechanisms have been recognized to be involved 
in TNF-a-induced suppression of osteoblast differentiation219. All the studies, including 
ours, could just reveal a tip of “iceberg”. More mechanisms are expected to be 
uncovered in future studies. Therefore, determining the relative contribution of JMJD3 
dysregulation is crucial to understanding its importance compared to other mechanisms 
and justifying possible epigenetic therapies in the management of MMBD. 
To accurately assess the role of JMJD3 downregulation in TNF-a-induced 
suppression of osteoblast differentiation, we ectopically overexpressed wild-type mouse 
JMJD3 in MC4 cells using lentiviruses and selected the colony that approximately 
maintains the baseline JMJD3 level after TNF-a treatment. Using a colony with dramatic 
increase in JMJD3 expression instead will exaggerate the importance of decreased 
JMJD3 expression in TNF-a-induced suppression of osteoblastogenesis. The gene 
expression of osteoblast marker genes and the ALP activity was subsequently compared 
between MC4 cells with or without JMJD3 overexpression in presence of TNF-a. Also, 
we purposely avoided using NF-kB inhibitors in these experiments since NF-kB 
activation should have unidentified effects on osteoblast differentiation independent of 
JMJD3. Using NF-kB inhibitors to determine the relative contribution of JMJD3 
downregulation to TNF-a-induced suppression of osteoblast differentiation will 
inevitably introduce confounding factors.  
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5.2 Results 
 
To determine the relative contribution of JMJD3 downregulation to TNF-a-
induced suppression of osteoblast differentiation, we used MC4/JMJD3 cells that stably 
overexpressed mouse wild-type JMJD3 and their control counterpart MC4/EV cells that 
harbored an empty vector. Both PCR and Western blot showed that MC4/JMJD3 cells 
maintained increased JMJD3 expression level following a 2-day treatment of 10 ng/ml 
TNF-a compared with MC4/EV cells (Figure 5-1A and B). Importantly, the mRNA and 
protein levels of Runx2 and Osterix were less inhibited by TNF-a in MC4/JMJD3 cells 
compared to MC4/EV cells (Figure 5-1A and B). TNF-a has been reported by others to 
inhibit ALP activity during induction of osteoblast differentiation. To determine if JMJD3 
overexpression in MC4 cells could rescue the impaired ALP activity in presence of TNF-a, 
we cultured MC4/EV or MC4/JMJD3 cells in osteogenic medium with or without 5 ng/ml 
TNF-a for 7 days.  5 ng/ml instead of 10 ng/ml TNF-a was used to minimize the cytotoxic 
effects of TNF-a on MC4 cells. In agreement with the expression data, ALP staining 
showed that the violet intensity that positively correlates with ALP activity was less 
inhibited by TNF-a in MC4/JMJD3 cells compared to MC4/EV cells (Figure 5-2). These 
data suggest that JMJD3 downregulation in stromal cells is partially responsible for the 
suppression of osteoblast differentiation induced by TNF-a. 
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Figure 5-1: JMJD3 Overexpression in MC4 Cells Partially Rescued the Inhibition of 
Runx2 and Osterix by TNF-a. 
 
MC4 cells stably infected with EV or JM were cultured in osteogenic medium with or 
without TNF-a for 2 days. The concentration of TNF-a used in each experiment is 
indicated in each graph. (A) The mRNA levels of JMJD3, Runx2 and Osterix were 
measured using qPCR with the geometric mean of the CT values of b-actin, GAPDH and 
HMBS as the internal control; (B) The protein levels of JMJD3, Runx2 and Osterix were 
measured by western with b-actin as the internal control; Error bars in each column 
graph represent SD of three biological replicates. * p < 0.05; ** p < 0.01; ***p < 0.001 
compared with the black bar in individual group. The numbers shown in the Western 
blot indicate normalized densitometry values. 
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Figure 5-2: JMJD3 Overexpression in MC4 Cells Partially Rescued the Suppression of 
Osteoblast Differentiation by TNF-a. 
 
MC4 cells stably infected with EV or JM were cultured in osteogenic medium with or 
without 5 ng/ml TNF-a for 7 days. (A) ALP staining was performed to assess ALP activity; 
(B) ImageJ software was used to quantify the intensity of ALP staining.  
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5.3 Discussion 
 
We treated MC4 cells with TNF-a or co-cultured them with 5TGM1 cells as the 
major in vitro model to study the persistently impaired osteoblast differentiation in 
MMBD. We have shown that JMJD3 expression in MC4 cells was decreased in response 
to prolonged TNF-a treatment or direct contacts with myeloma cells. The decreased 
expression of JMJD3 contributed to the resolution of the bivalent domains at the Runx2 
and Osterix TSSs to transcriptionally silent domains. Silencing JMJD3 in MC4 cells 
sufficed to inhibit normal osteoblast differentiation. Based on the findings above, it’s 
reasonable to conclude that JMJD3 dysregulation and resulting epigenetic changes are 
involved in the suppression of osteoblast differentiation mediated by TNF-a or MM cells. 
Our recent finding showing the partial rescue of osteoblast differentiation by 
overexpressing JMJD3 in MC4 cells further supports this notion. Consistent with the in 
vitro findings, BMSCs isolated from MM patients (MM-BMSCs) expressed significantly 
lower levels of JMJD3 compared to BMSCs isolated from age-matched healthy donors. 
Of note, loss of JMJD3 expression persisted in MM-BMSCs even after they were 
continuously cultured without CD138+ MM cells for more than one month. The lasting 
nature of JMJD3 dysregulation and the accumulation of dynamically stable H3K27 marks 
on the Runx2 and Osterix TSSs in BMSCs at least partially explains the protracted bone 
lesions in MM patients having acquired complete remission. In summary, our study 
provides the initial insight into how the suppression of osteoblast differentiation is 
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maintained in MM patients. Developing strategies to target JMJD3 or its upstream 
regulators could potentially mitigate MMBD and associated comorbidities.  
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CHAPTER 6 
CONCLUDING REMARKS ON FUTURE RESEARCH DIRECTIONS AND POTENTIAL CLINICAL 
TRANSLATION OF JMJD3 IN MMBD  
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6.1 Future Research Direction of JMJD3 in MMBD 
 
We report a novel mechanism that contributes to the persistence of lytic bone 
lesions in MM patients even after they achieve complete remission. We have found that 
BMSCs from MM patients express significantly lower levels of the H3K27 demethylase 
JMJD3 than BMSCs from healthy donors. Decreased JMJD3 expression inhibits the gene 
expression of Runx2 and Osterix, the master transcription factors of osteoblast 
differentiation, by resolving the bivalent domains on their promoters to transcriptionally 
silent domains. Our results further demonstrate that the NF-kB-JMJD3-Runx2/Osterix 
axis is a major contributor to the prolonged suppression of osteoblast differentiation in 
MM and provides a potential new therapeutic target for treating MMBD. Studying the 
role of JMJD3 in MMBD, however, only opens more questions that need to be properly 
addressed in future research. Currently we have three directions worthy of pursuing. 
Investigating the fundamental functions of JMJD3 will help us better understand the 
pathophysiology of MMBD. Moreover, this knowledge should also be useful in 
understanding other diseases since JMJD3 is actively involved in malignancy, senescence, 
inflammation, trauma and fetal development. 
Human JMJD3 protein has 22 phosphorylation sites throughout the entire 
protein length based on low- and high- throughput MS data collected over 16 years. This 
information has not been pursued to date by researchers. Nearly all existing studies 
related to JMJD3 solely focus on examining its expression change in different cellular 
states. Our study is no exception so far. However, the biological effects of 
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phosphorylation of these sites is poorly understood. It’s possible that TNF-a or direct 
contacts with myeloma cells could affect JMJD3 enzymatic activity by phosphorylating 
key amino acids. Group-based Prediction System 3.0 (GPS 3.0) which is used to predict 
proteins’ cognate kinases reveals that JMJD3 can be phosphorylated by JNK, p38, ERK 
and IKK with high confidence (data not shown). Combining JMJD3 immunoprecipitation 
and Western blot using anti-phospho-(Ser/Thr) antibodies would allow us to compare 
the levels of phosphorylated JMJD3 in BMSCs exposed to TNF-a or myeloma cells with 
the levels of phosphorylated JMJD3 in control cells. To correlate the phosphorylation 
status of JMJD3 with its enzymatic activity, In vitro histone demethylase assay220 could 
be performed by incubating purified JMJD3 protein with H3K27me3 H3 substrates in a 
reaction supplemented with Fe (II) and a-ketoglutarate. Following the reaction, the 
JMJD3 demethylase activity could be detected by immunoblotting the histone 
substrates using anti-H3K27me3 antibodies. Furthermore, transfection of truncated and 
mutated JMJD3 into stromal cells will help localize the phosphorylated site(s) induced by 
TNF-a treatment and direct contacts with myeloma cells.  
The second potential future research direction is to investigate the detailed 
molecular mechanism(s) by which NF-kB activation inhibits JMJD3 gene expression. We 
found that TNF-a initially induces JMJD3 expression within 6-hours of exposure and 
suppresses its expression thereafter via NF-kB signaling. The time-dependent regulation 
of JMJD3 reveals different effects of short- and long-term inflammation on epigenetics 
in cells. One hypothesis is that persistent NF-kB activation inhibits the transcription of 
its target genes by remodeling the histone methylations on their promoters. Levy et al. 
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have reported that mono-methylation of activated p65 by SETD6 in nucleus recruits the 
H3K9 methyltransferase GLP and subsequently introduces transcriptionally repressive 
mark H3K9me to their target genes187. Based on this evidence, activated p65 in stromal 
cells may recruit GLP to the JMJD3 promoter and shut down its gene expression. To test 
this hypothesis, the methylated p65 levels in the nucleus could be examined by Western 
blot in stromal cells with or without SETD6 knockdown. ChIP could be performed to 
compare the occupying levels of H3K9me, GLP, p65 and RNA polymerase II (Pol II) Ser 2 
on the JMJD3 gene in stromal cells treated with vehicle or TNF-a. Increased H3K9me 
and GLP on the JMJD3 promoter, and decreased Pol II Ser 2 on the JMJD3 gene body in 
stromal cells previously exposed to TNF-a should support this hypothesis. Another 
hypothesis for the effects of TNF-a on JMJD3 is that activated p65 interferes the DNA 
binding of SMADs to the JMJD3 promoter by sequestering SMADs into a complex217. 
Independent studies have reported that SMADs activate JMJD3 gene expression by 
binding to its promoter. Therefore, disruption of this process presumably downregulates 
JMJD3 expression. To test this hypothesis, one could examine the direct binding of 
activated p65 with SMAD1/4 by immunoprecipitation and the occupancy of SMAD1/4 
on the JMJD3 promoter by ChIP in BMSCs treated with or without TNF-a. Decreased 
SMADs occupancy on the JMJD3 promoter after TNF-a treatment would support this 
hypothesis. 
Lastly, loss of JMJD3 expression in stromal cells may “lock” them into a precursor 
state. Zhao et al. reported that knockdown of JMJD3 in MEFs significantly promotes 
their reprogramming into inducible pluripotent stem cells (iPSCs), as evidenced by 
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increased number of positive colonies. Conversely, ectopic overexpression of JMJD3 in 
MEFs markedly inhibits reprogramming efficiency221. These findings suggest that JMJD3 
can be generally considered as a promoter of cell differentiation. In line with this 
argument, loss of JMJD3 expression in BMSCs should result in these cells expressing an 
immature phenotype. Supporting our hypothesis, our preliminary data showed that the 
marker genes of mouse BMSCs, namely Nestin222, Prx1223, Sca1224 and PDGFRa224, were 
induced in MC4 cells after TNF-a treatment for 2 days (Figure 6). In addition, Xu et al. 
have reported that CD166, a human BMSC marker gene, is highly expressed in MM cell 
lines and stromal cells isolated from MM patients225. To establish the causal relationship, 
one could examine if knockdown of JMJD3 alone is sufficient to induce the expression of 
BMSC marker genes. Also, isolation of BMSCs from age-matched healthy donors and 
MM patients would allow comparison of the abundancy of human BMSC surface 
markers by flow cytometry. 
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Figure 6: TNF-a Increases the Expression of Mouse BMSC Marker Genes. 
 
MC4 cells were treated with or without 10 ng/ml TNF-a for 2 days. The mRNA levels of 
Nestin, Prx1, Sca1 and PDGFRa were measured using qPCR with the geometric mean of 
the CT values of b-actin, GAPDH and HMBS as the internal control. Error bars in each 
column graph represent SD of three biological replicates. * p < 0.05; ** p < 0.01; ***p < 
0.001 compared with the black bar in individual group. # p < 0.05; ## p < 0.01; ### p < 
0.001 compared with the grey bar in individual group. 
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6.2 Potential Epigenetic Therapies in the Management of MMBD 
 
The epigenome in cells possesses a certain degree of plasticity to incorporate 
new information from the surrounding environment. This feature makes epigenetic 
therapy a legitimate approach to reverse an established pathological status. To date, 
five compounds selectively targeting the enzymes involved in epigenetic regulation have 
been approved by the US Food and Drug Administration (FDA) to treat hematological 
malignancies. These compounds include two DNMT inhibitors (Azacitidine and 
Decitabine) and three HDAC inhibitors (Vorinostat, Romidepsin and Belinostat)226.  
Azacitidine227 and Decitabine228 are both cytidine analogs that covalently sequester 
DNMTs, trigger DNMT degradation and cause reduction in DNA methylation. In a 
randomized controlled clinical trial determining the efficacy of Azacitidine in treating 
myelodysplastic syndrome (MDS), 16% of patients receiving subcutaneous Azacitidine 
partially or completely restored their blood cell counts and bone marrow morphology to 
normal compared to none of patients only receiving supportive care229. The improved 
clinical outcome through solely modulating epigenetics demonstrates a novel 
therapeutic strategy to treat diseases. Further supporting this notion, intravaneous 
administration of Belinostat increases the overall response rate (ORR) of patients 
diagnosed with peripheral T-cell lymphomas230.  
Besides these officially approved epigenetic agents, several inhibitors of histone 
modifiers are currently undergoing preclinical and clinical trials. These small molecule 
inhibitors specifically target G9a, EZH2, DOT1L or LSD1, and show anti-tumor activity as 
107 
a single agent or in combination with other standard chemotherapies. These 
compounds are also being actively tested in the medical conditions other than 
malignancy, in which epigenetic alterations have been reported to play a pivotal role in 
disease pathogenesis and progression. The success of epigenetic therapy relies on not 
only the continuous development of specific, well-tolerated compounds that target key 
epigenetic enzymes, but also the growing knowledge of how epigenetics is involved in 
each disease. In this dissertation, we have shown that the downregulation of JMJD3 in 
BMSCs suppresses osteoblast differentiation by resolving the bivalent domains on the 
Runx2 and Osterix promoters to transcriptionally silent domains in MMBD. Ectopic 
JMJD3 overexpression in BMSCs partially overcomes the inhibitory effects of MM on 
osteoblast differentiation. Our findings provide the first theoretical basis that targeting 
JMJD3 could potentially benefit the healing process of lytic bone lesions in MMBD 
patients. Also, we and our colleagues have collectively reported that Gfi1 mediates MM-
induced long-term suppression of osteoblast differentiation by recruiting co-repressors 
EZH2 and HDACs to the Runx2 promoter. These findings suggest that administration of 
EZH2 or HDAC inhibitors in MMBD patients might be promising to control this dire 
complication. Considering the availability of FDA-approved HDAC inhibitors and the 
EZH2 inhibitor Tazemetostat231 currently undergoing phase II clinical trials, determining 
the efficacy of these compounds in treating MMBD will significantly shorten the lengthy 
process of drug development.  
There exist many challenges for epigenetic therapies, the major one being “off-
target” effects. This issue is inherent in the compounds developed to target epigenetic 
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enzymes due to the conserved amino acid sequences shared by these enzymes with 
different substrate specificity. One elegant example is the carefully designed H3K27 
demethylase inhibitor GSK-J1 based on crystal structures. GSK-J1 works by masking the 
binding sites of JMJD3 for both a-ketoglutarate and Pro 30 (P30) of H3 tails. The original 
study showed that the half-maximum inhibitory concentration (IC50) of GSK-J1 was 60 
nM in the JMJD3 AlphaScreen assay. Further, GSK-J1 didn’t significantly inhibit 100 
protein kinases at a concentration of 30 µM and had negligible off-target activity against 
other chromatin-modifying enzymes232. However, the specificity of GSK-J1 was 
subsequently questioned by another study showing that GSK-J1 inhibited the activity of 
the H3K4 demethylase KDM5B and the H3K9/36 demethylase KDM4C with a similar 
extent to JMJD3/UTX in cells233. To make things more complicated, histone modifiers are 
not limited to modifying only histones, they can also modify non-histone proteins234-236. 
Deregulated modifications of non-histone proteins unavoidably invite unwanted side 
effects. Lastly, maintaining epigenetic homeostasis is important in normal cell function. 
Epigenetic therapies in the management of MMBD can equally affect cells other than 
BMSCs in bone marrow microenvironment. The effects of epigenetic therapies on each 
cell subpopulation must be thoroughly examined and the benefits/risks be assessed 
before they can be considered for testing in patients.  
Our findings showing the inhibition of JMJD3 gene expression by NF-kB 
activation provide an alternative strategy to overcome the challenges met in epigenetic 
therapies. Instead of targeting the key enzyme itself, targeting its upstream regulators 
gives a higher chance of developing a specific, well-tolerated, FDA-approved compound 
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simply because there are more targets to work on. In the management of MMBD, NF-kB 
activation can be inhibited using small molecules to restore JMJD3 expression in BMSCs. 
While no selective JMJD3-activating compound has been developed, over 20 inhibitors 
are readily available to block NF-kB activation through different mechanisms, including 
inhibition of IKK complex, IkB degradation, NF-kB nuclear translocation, p65 acetylation, 
NF-kB DNA binding, and NF-kB transactivation. In addition, 19 FDA-approved drugs have 
been reported to show inhibitory effects on NF-kB with IC50 ranging from 0.02 to 40 
µM237. 
As new compounds that target epigenetics become available and our 
understanding of MMBD increases, epigenetic therapies are promising agents to be 
applied to the management of MM patients and could show efficacy in healing 
protracted lytic bone lesions. Epigenetic therapies could correct the dysregulated 
histone methylations in BMSCs from MM patients without the need of depleting the 
BMSC population. Following treatment, the BMSCs restore their capacity of 
osteoblastogenesis and cease secreting cytokines to support MM growth. As a result, 
epigenetic therapies might also decrease tumor burden and improve 5-year survival 
rates for MM patients.  
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APPENDIX 
Gene Forward sequence (5'-3') Reverse sequence (5'-3') 
mbeta-actin CTCTGGCTCCTAGCACCATGAAGA GTAAAACGCAGCTCAGTAACAGTCCG 
mJMJD3 CTGCACCTTGAGCACAAACG CTAAGGCCCTCCTCTCCTGA 
mUTX TTAGTAAGTGAAATCAACATGCTCC TCAAGATGAGGCGGATGGTA 
mEZH2 TCCATGCAACACCCAACACAT CTCCCTCCAGATGCTGGTAAC 
mEED GGGCGATTTGATTACAGCCAG TGCCCAATGCAAGCATCTTT 
mSuz12 AGAGCAAGAATCTCATAGCTTGTC GCAGGACTTCCAGGGTAACA 
mRunx2 AGGGACTATGGCGTCAAACA AGAAGCTTTGCTGACACGGT 
mOsterix AGAGGTTCACTCGCTCTGACGA TTGCTCAAGTGGTCGCTTCTG 
mGfi1 GGCTCCTACAAATGCATCAAATG TGCCACAGATCTTACAGTCAAAG 
mTNF-a TAGCCCACGTCGTAGCAAAC ACAAGGTACAACCCATCGGC 
mA20 CTCAGAGAGGCGCCAAAAGA TTTGAGGAGCCAAGTCCCAC 
mIL-6 CAAAGCCAGAGTCCTTCAGA GCCACTCCTTCTGTGACTCC 
   ChIP primers Forward sequence (5'-3') Reverse sequence (5'-3') 
Runx2 p -
670 AAGGCAAACAGAAGGAAGCA TGCTGCTTTGCAGTAATTCG 
Runx2 p -
336 GGCTCCTTCAGCATTTGTGT TCCCTTTCTCCCTCTGACAA 
Runx2 p 51 CTTCATTCGCCTCACAAACA TAAACGCCAGAGCCTTCTTG 
Runx2 p 
33130 AGGTAGCCCAGCAAAAACCT CCCCTCTGTGAGCCAAAATA 
Osterix p -
428 GCCACCCATTGCCAGTAATCT ACCTGGGTAGGCTAGGGTTG 
Osterix p -
306 TGGGGTATGTAGGACTCCCG CTTCCTTGGGGGTGCTATGG 
Osterix p -96 ATCCGGAGTCTTCTCCGCT TGTCTGTAGGGATCCACCCTC 
Osterix p144 GGCGTCCTCTCTGCTTGAG GGTGGGGTAGGCATGGATTAG 
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